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ABSTRACT 
Hypertrophic cardiomyopathy (HCM) is the most common genetic disease of 
the myocardium. In ~60% of the cases HCM is caused by mutations in 
sarcomeric proteins, such as cardiac Myosin Binding Protein C (cMyBPC), 
which are responsible for generating the molecular force of myocyte 
contraction. A cohort of HCM patients have been screened for mutations in 
sarcomeric genes, and some new variants of cMyBPC of uncertain significance 
(VUS) were found. These new variants include two intronic variants 
(MYBPC3-c.506-2 A>C and MYBPC3-c.2308+3 G>C) and one missense 
variant (cMyBPC I603M), which were selected for functional study to 
determine pathogenicity.  
 
The MYBPC3-c.506-2 A>C mutation was analysed in mRNA extracted from 
peripheral blood of the patient. The analysis revealed the loss of the canonical 
splice site and the utilization of an alternative splicing site, causing the loss of 
the first 7 nucleotides of exon 5. For the other variant, minigene constructs 
were generated to transfect HEK-293 cells. The minigene assay showed that 
mutation MYBPC3-c.2308+3 G>C also produces altered pre-mRNA 
processing, resulting in the skipping of the exon 23. 
 
The mutation I603M localizes to domain C4 of cMyBPC. Using 
bioinformatics sequence analyses, a deleterious effect for I603M was 
predicted, but mRNA studies do not show any alteration of the splicing 
mechanism. At the protein level, homology modelling of domain C4 shows 
I603 to be buried in the protein structure, suggesting a potential destabilizing 
role of the I603M mutant. Indeed, circular dichroism spectroscopy and 
differential scanning calorimetry show a ~15ºC lower melting temperature for 
the mutant C4 domain. Finally, results obtained by single-molecule atomic 
force microscopy do not show a mechanical fingerprint for C4 indicating a 
very low mechanical stability of this domain. 
 
Taken our results together, we propose that mutations c.506-2 A>C, c.2308+3 
G>C and I603M lead to haploinsufficiency and cMyBPC protein 
destabilization, respectively causing the development of HCM.  
 
In conclusion, the study of the functional consequences of mutations leads to 
assignment of pathogenicity of variants of uncertain significance. 
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ABBREVIATIONS 
ACMG American College of Medical Genetics and Genomics 
ACTC1 cardiac α-actin gene 
AFM  Atomic Force Microscopy  
BPS  Branch site 
CD  Circular Dichroism  
DHPR  Dihydropyridine receptor 
DSC  Differential scanning calorimetry  
HBB  Human β-globin gene 
HCM  Hypertrophic cardiomyopathy 
HGMD Human Gene Mutation Database 
LMM  Light meromyosin 
LVH  Left ventricle hypertrophy  
MHC-α α-myosin 
MHC-β ß-myosin 
MyBPC Myosin-binding protein C  
MYBPC3  Cardiac myosin-binding protein C gene  
MYH6 Cardiac α-myosin heavy chain gene 
MYH7  Cardiac ß-myosin heavy chain gene 
MYL2  Regulatory myosin light chain gene 
MYL3  Essential myosin light chain gene 
PMI  Precision Medicine Initiative 
PPT  Polypyrimidine tract 
PTC  Premature termination codons  
RLC  Myosin regulatory light chain 
RyR2  Ryanodine receptor 
SCD  Sudden cardiac death  
SR  Sarcoplasmic reticulum 
  4 
SRX  Superrelaxed tate 
Tm  Temperature at the midpoint of thermal transition  
Tm  Tropomyosin 
TnI  Troponin I 
TNNI3 Cardiac troponin I gene 
TNNT2 Cardiac troponin T gene 
TnT  Troponin T 
TPM1  Cardiac α tropomyosin gene 
UsnRNP Uridine-rich small ribonucleoproteins 
VUS  Variants of uncertain significance 
WLC  Worm-like chain model of polymer elasticity 
ΔHcal  Calorimetric enthalpy  
ΔHv  Van’t Hoff enthalpy  
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INTRODUCTION 
In the 1950s, using high-resolution microscopy, two independent groups of 
scientists observed changes in sarcomere length during contraction (Huxley 
and Hanson 1954; Huxley and Niedergerke 1954). The sarcomere is the 
contractile unit of striated muscle, defined as the distance between two regions 
called Z-disks or Z-lines. These regions consist of a central A-band, made up 
of myosin, flanked by two I-bands, which are composed by actin filaments 
(Figure 1) (Sweeney and Hammers 2018). Huxley and colleagues observed 
that during sarcomere contraction, the length of the A-band remains constant 
while the I-band shortens (Krans 2010).  Since x-ray diffraction studies proved 
inextensibility of both thick and thin filaments of striated muscle, they 
established the “sliding filament theory” as the interaction of myosin and actin 
that induces shortening of the sarcomere, and thus the muscle, through the 
sliding of thick filaments on thin filaments (Mijailovich et al. 1996; Lin et al. 
2017). Other elements of myofilaments were subsequently discovered to be 
involved in this mechanism.  
 
 
Figure 1: Electron micrograph of the sarcomere of skeletal muscle. A longitudinal 
thin section through a muscle fibre is shown. The major bands and lines are indicated 
as Z, Z-line, M, M-line, A-band, I-band and H-zone (Figure adapted from Sweeney 
and Hammers 2018) 
 
Almost simultaneously to the Huxleys’ research on sarcomere function during 
the 1950’s, Robert Donald Teare, an English pathologist at St. George’s 
Hospital in London, reported an autopsy of eight patients with asymmetrical 
hypertrophy of the heart and disorganized arrangement of muscle bundles 
associated with hypertrophy of individual muscle fibres and their nuclei 
(Figure 2). Seven of these caused sudden death in young adults (Teare 1958).  
Introduction 
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The disease that affected these patients was recognised as a distinct pathology, 
later named Hypertrophic Cardiomyopathy (HCM).  
 
   
Figure 2: heart of the first HCM patient with localized hypertrophy of the 
interventricular septum (on the left). On the right is shown the disordered arrangement 
of muscle bundles of the same patient (Figure adapted from Teare 1958). 
It was not until years later that the relationship between sarcomere defects and 
the development of hypertrophic cardiomyopathy was discovered.  
 
1.1 The Sarcomere: the contractile unit of striated muscle 
There are three types of muscle: skeletal, cardiac, and smooth. Skeletal and 
cardiac muscle are referred to as striated muscle because of the regular 
organization of sarcomeres. These contractile units consist of highly organized 
components that interact in a very precise manner to generate force and motion. 
Sarcomeres also integrate many signalling functions in muscle. Indeed, they 
are connected with other organelles, such as mitochondria or nucleus, by 
intermediate filaments to maintain cellular integrity and to contribute to 
mechanotransduction (Sweeney and Hammers 2018). 
 
The sarcomere has three major filament systems that include thin filaments, 
thick filaments and the giant protein titin. The thin and thick filaments extend 
from the Z-disk and M-line, respectively, overlapping on each side of the M-
line and creating distinctive regions within the sarcomere (Figure 3) 
(Henderson et al. 2017; Lin et al. 2017). 
 
The primary component of thin filaments is actin, a helical rope-like structure 
Introduction 
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attached to the Z-disks. Actin monomers (G-actin) polymerize into long 
filaments (F-actin) at physiological ionic strength and in the presence of Mg2+ 
and K+, forming a tightly wound helix (Roberto Dominguez and Kenneth C. 
Holmes 2011). G-actin consists of four subdomains (SD1- SD4) that form a 
binding pocket for ADP or ATP as well as the divalent ions Mg2+ and Ca2+. 
The region SD1 and SD2 also interact with other myofilament proteins, such 
as myosin and myosin binding protein C (MyBPC). Specifically, actin SD1 
binds to the myosin head, also known as myosin S1 via ionic interactions (Lin 
et al. 2017). Three homologous isoforms of actin (α, β and γ) are expressed in 
vertebrates. The α-actin, in turn, consist in skeletal, cardiac, and smooth 
variations. Skeletal and cardiac isoforms are differentially expressed: ACTC1 
gene encodes α-cardiac-actin, whereas α-skeletal-actin is expressed by ACTA1 
gene (Henderson et al. 2017). 
 
Other thin filament proteins, tropomyosin (Tm) and troponin (Tn), regulate 
the contraction of striated muscle. Tropomyosin is an elongated coiled-coil 
molecule that binds to the surface of the thin actin filament (Figure 3 and 
Figure 4). Troponin comprises three subunits: troponin T (TnT), which binds 
to tropomyosin; troponin I (TnI), which binds to both actin and tropomyosin; 
and troponin C (TnC), which confers Ca2+ sensitivity to the system (Sweeney 
and Hammers 2018). 
 
 
 
Figure 3: schematic diagram depicting the three major filament systems found in 
sarcomeres. Thin filament (gray), thick filament (blue), titin (pink) (Figure adapted 
from Henderson et al. 2017). 
 
Myosin is the main component of the thick filament. Myosin is the molecular 
motor that drives muscle contraction trough interaction with thin filaments. 
Myosin is composed of heavy chain fragment (MHC) and light chain fragment 
(MLC). Myosin heavy chain consist of three regions: N-terminal head (S1), 
Figure 1. 
(A) Schematic representation of a cardiac sarcomere (lacking nebulin) illustrating the three 
major filament systems: actin-based thin filaments (gray), myosin-based thick filaments 
(blue), and titin (pink). The lateral boundaries of the sarcomere are the Z-discs. The I-bands 
surrounds the Z-disc and is a region where thin filaments are not superimposed by thick 
filaments. The A-band region contains thin filaments and thick filaments. The M-band falls 
within the H-zone, where thick filaments do not interdigitate with thick filaments. (B) 
Electron micrograph of skeletal muscle sarcomere. (C) Enlarged view of the M-band region. 
The M-band is composed of a series of three to five electron-dense M-lines: M6′, M4′, M1, 
M4, and M6. [Part A modified, with permission, from (255); Parts B and C modified, with 
permission, from (9).]
Henderson et al. Page 91
Compr Physiol. Author manuscript; available in PMC 2018 April 09.
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neck (S2) and a C-terminal long tail region known as light meromyosin (LMM) 
(Figure 4). The S1 subfragment projects outward from the thick filament and 
contains a motor domain that binds actin filaments to form cross-bridges. This 
interaction drives actin-based movement via ATP hydrolysis. The neck region 
transduces force through its lever arm and the highly variable tail region 
mediates myosin interactions. Myosin light chains regulate MHC motor 
function by binding to the neck region (Henderson et al. 2017). 
 
Two major isoforms of myosin are present in heart muscle: α-myosin (MHC-
α) and ß-myosin (MHC-β) expressed by the MYH6 and MYH7 genes, 
respectively. In cardiac muscle of small mammals (e.g., mice), MHC-β is the 
predominant isoform during development and is replaced by MHC-α in the 
adult. In large mammals such as humans, MHC-α is expresses during 
development while MHC-β is the predominant isoform in the adult heart. In 
failing hearts (mouse and human), MHC can shift to the fetal isoform as a 
maladaptive response to severe cardiovascular stress (Lin et al. 2017). 
 
Another component of the thick filament is the myosin-binding protein 
family (MyBP). This family consists of myosin-binding protein C (MyBPC) 
and myosin-binding protein H (MyBPH). Both MyBPs are located within the 
C-zone of A-band region and are arranged in 7 to 9 transverse stripes spaced 
at 43-nm intervals. There are three isoforms of MyBPC: a slow skeletal 
isoform, a fast skeletal isoform and a cardiac isoform, encoded by the distinct 
genes MYBPC1, MYBPC2, and MYBPC3, respectively. There is only one 
isoform of MyBPH (human gene MYBPH) expressed in the Purkinje fibers 
and fast twitch skeletal muscle fibers. MyBPC is thought to link the thick and 
thin filament systems and further regulate cross-bridge cycling by displacing 
tropomyosin and competing with myosin for actin binding. Specifically, the 
N-terminus of MyBPC binds actin filaments, regulating contraction by altering 
the actin-activated myosin ATPase activity. MyBPC’s N-terminal M-motif 
also interacts with the S2 region of myosin, leading to regulation of the 
contraction. The C-terminus of cMyBPC binds titin and is necessary to localize 
MyBPC to the A-band (Figure 4). This interaction also allows MyBPC to 
possibly work in concert with all of the filament systems during contraction to 
impact force development, transmission, sensing, and signalling (Henderson et 
al. 2017). 
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Figure 4: representation of structure and binding of thin and thick filaments proteins 
(Figure adapted from Lin et al. 2017). 
 
Titin is the third myofilament system in the sarcomere spanning the length of 
the half sarcomere: the N-terminal region anchors to the Z-disk and extends 
across the I-band and A-band toward the M-line (Figure 3). The elastic I-band 
region of titin consists of a combination of tandem immunoglobulin domains 
(Ig), and random coil regions such as the PEVK (Figure 5). The PEVK region 
consists of approximately 70% proline (P), glutamic acid (E), valine (V), and 
lysine (K) residues, thus the name. The Ig domains and the random coil regions 
are crucial extensible sites conferring elasticity to the I-band region of titin. 
Titin within the A-band is composed of super repeats of seven fibronectin III 
domains (Fn3) and four Ig domains. This inextensible portion of titin interacts 
with MyBPC and the myosin tail domains, thus linking titin to the thick 
filaments. Differential splicing of the single titin gene (TTN) produces titin 
isoforms of different lengths. In adult cardiac muscle, two different splicing 
isoforms coexist (N2B and N2BA), which differ in their I-band regions. The 
N2B is the stiffest and shortest isoform (3.0 MDa), which is characterised by 
the absence of N2A element. N2BA is the longest isoform (3.3 to 3.5 MDa) 
and includes both N2A and N2B fragments. 
 
Titin is thought of as a “molecular spring” and is key to the passive mechanical 
properties of the myofilaments contributing to passive tension during diastolic 
relaxation (Henderson et al. 2017; Lin et al. 2017). 
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Figure 5: schematic structure of Titin containing N2B and PEVK regions. Interactions 
with thick and thin filaments are also represented (Figure adapted from Lin et al. 
2017). 
1.1.1 Sarcomere contraction and relaxation 
The sarcomeres are responsible for contraction of muscle cells through a 
process known as excitation-contraction coupling. This process occurs via 
electrical stimulus linked to mechanical contraction movement. The process 
starts when an electrical signal, modulated in part by autonomic innervation, 
induces calcium release. The electrical signal results in an initial inward flux 
of Ca2+ from voltage-dependent Ca2+ channels, known as dihydropyridine 
receptors (DHPR). This initial ion flow is detected by ryanodine receptors 
(RyR2 in the heart), that release Ca2+ stores from the sarcoplasmic reticulum 
(SR) (Lin et al. 2017). The rising levels of Ca2+ initiate contraction by binding 
the amino-terminal Ca2+ binding-site of TnC within the Tn complex. The TnC 
consist of two globular domains (N- and C-terminal domains) connected via 
an α-helical bridge. The N-terminal region is a regulatory domain, whereas the 
C-terminal motif has a structural role by anchoring TnC to TnI. The binding of 
Ca2+ to the N-terminal globular domain partially opens a hydrophobic region 
of TnC and alters its interaction with TnI, which induces TnI movement. The 
shift of TnI is transmitted to Tm by TnT. When Ca2+ binds to TnC, TnT 
disengages from interaction with Tm, allowing Tm to move its position relative 
to actin, such that its myosin-binding site is exposed (Figure 6) (Dupuis et al. 
2016; Lin et al. 2017). During this phase of contraction, myosin heads are in a 
pre-power stroke conformation in which the myosin binds ADP and Pi. Release 
of Pi hydrolytic product facilitates myosin head binding at a new position along 
the actin filament, and a myosin power stroke pulls Z-lines toward each other 
resulting in sarcomere shortening and muscle contraction. Finally, myosin 
releases ADP allowing new ATP binding and dissociation of the myosin head 
from actin. Myosin ATPase then hydrolyzes ATP, prompting the myosin 
head’s converter domain to change shape. ATP hydrolysis enables the myosin 
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head to re-adopt a pre-power stroke conformation, so a new ‘cross-bridge 
cycle’ can be repeated (Garfinkel et al. 2018). 
 
 
Figure 6: schematic representation of Troponin complex activation. (Left) At rest, the 
actin monomer (in red) is blocked by troponin complex. (Right) A conformational 
change in the Tn complex removes the Tm from the blocking position (Figure adapted 
from Dupuis et al. 2016). 
 
Muscle contraction is triggered and regulated by calcium levels and Ca2+-
sensor proteins. The calcium regulatory system acts in a length-dependent 
fashion by which elongated sarcomeres exhibit increased calcium sensitivity. 
Although the major gatekeeper of the calcium-based regulation is troponin-
tropomyosin complex, cMyBPC and titin have been shown to participate in 
Ca2+-mediated regulation of contraction. Essentially, cMyBPC 
phosphorylation increases myofilament calcium sensitivity and, at short 
sarcomere lengths, titin reduces the length-dependence of the calcium 
regulatory system (Figure 7) (Garfinkel et al. 2018). 
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Figure 7: schematic drawing of the actomyosin cross-bridge cycle. Rest state (1), 
transition state (2), active state (3) and active state with loss of bound Ca2+ (4) are 
represented (Figure adapted from Henderson et al. 2017). 
 
At low myofilament calcium concentrations, tropomyosin blocks the myosin-
binding site on actin and results in sarcomere relaxation. Two distinct 
structures of paired and relaxed myosins have been identified, each associated 
with different rates of energy consumption (Figure 8). The disordered relaxed 
(DRX) state occurs when one myosin head interacts with the thick filament 
backbone, resulting in steric inhibition of its ATPase, whereas its partner 
myosin retains ATP hydrolysis activity and the potential for actomyosin 
interactions and force production. The superrelaxed (SRX) state occurs when 
both myosin heads dock onto the thick filament backbone, inhibiting ATP 
hydrolysis and withdrawing both myosins from thin filament interaction and 
force production (Garfinkel et al. 2018). 
 
Figure 14. 
Schematic drawing of the cardiac cross-bridge cycle. Thin-filaments are shown with actin, 
tropomyosin (Tm) and the troponin (Tn) complex with the Ca2+-binding unit (cTnC) in 
pink, the Tm-binding unit (cTnT) in blue, and the inhibitory unit (cTnI) in light green. 
Thick-filament cross-bridges (XB) are shown with myosin heavy chain (MHC; figure 
illustrating one MHC) in red, yosin light chains (LC) in green, along with myosin-binding 
protein C (MyBP-C) in purple and titin in orange. Cross-bridges are initially in a rest state 
(1) where they are weakly bound and do not generate force. Cross-bridges enter a transition 
state (2) determined by the on (kCa) and off rates (kCa-1) for Ca2+ exchange with cTnC. 
During this transition state, cross-bridges are weakly bound (kXB-1) and do not generate 
force. In the active state (3), the cTnT-dependent shift of Tm from its blocking position on 
actin filaments allows strong cross-bridge binding (kXB) and induces cooperative activation 
of the thin filament (e.g., increase Ca2+ affinity of cTnC; kCa-XB-1). In the active state (4) 
with loss of bound Ca2+, the cooperative mechanisms allow a population of cross-bridges to 
remain active and force generating (kCa-XB). Mechanical feedback termed shortening-
induced deactivation (kvel) will transition active cross-bridges back to the resting state. [Fig. 
modified, with permission, from (265).]
Henderson et al. Page 108
Compr Physiol. Author manuscript; available in PMC 2018 April 09.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Introduction 
 15 
 
Figure 8: representation of sarcomere conformations and associated energy 
consumption throughout the cardiac cycle (Figure adapted from Garfinkel et al. 2018). 
1.2 Hypertrophic Cardiomyopathy (HCM): definition and clinical 
manifestations  
HCM is the most common inherited cardiovascular disease with an estimated 
prevalence ranging from 1:500 to 1:200 and the most frequent cause of sudden 
cardiac death (SCD). The risk of SCD is high in young patients, including 
athletes, and it may be the first manifestation of the disease (Wijnker et al. 
2018). 
 
The clinical manifestations of HCM are highly variable. Many patients are 
asymptomatic and are diagnosed incidentally, others may manifest shortness 
of breath, chest pain, palpitations or syncope, triggered by left ventricle 
hypertrophy (LVH). LVH typically manifests as asymmetric hypertrophy with 
greatest involvement of the basal interventricular septum subjacent to the 
aortic valve. At the cellular level, histopathologic study of heart muscle in 
HCM demonstrates that cardiac myocytes are hypertrophied, disorganized, and 
separated by areas of interstitial fibrosis (Geske et al. 2018). 
 
Approximately, 5%-10% of patients with HCM progress to end-stage disease 
with impaired systolic function and dilatation. Atrial fibrillation is present in 
nearly 1 of 5 patients, accompanied by significant risk of stroke (Sabater-
Molina et al. 2018). 
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1.2.1 Genetics bases of HCM 
The first evidence of genetic involvement in Hypertrophic Cardiomyopathy 
was published in 1989, where a genetic-linkage analyses identified a locus on 
chromosome 14 that was inherited with hypertrophic cardiomyopathy in over 
100 family members (Jarcho et al. 1989). Many genomic studies in the decades 
following have found that the majority of HCM cases are caused by mutations 
in sarcomere protein genes that cause HCM in an autosomal dominant pattern. 
For that reason, Hypertrophic Cardiomyopathy is recognized as a disease of 
the sarcomere (Ingles et al. 2018). 
 
To date, most pathogenic variants detected in HCM patients affect by cardiac 
myosin-binding protein C (MYBPC3) and β-myosin heavy chain (MYH7) 
genes, together being responsible for approximately half of the familial HCM 
cases. Mutations in troponin T, troponin I, and Tm (TNNT2, TNNI3, TPM1) 
constitute less than 10% of diagnosed HCM cases. Other genes whose 
mutations cause HCM include MYL2 (myosin light chain 2), MYL3 (myosin 
light chain 3), and ACTC1 (cardiac α-actin), although with a much lower 
frequency (1%-5% each) (Table 1) (Liew et al. 2017). 
 
Table 1: Mutations in sarcomeric genes that cause Hypertrophic Cardiomyopathy  
Gene Protein Frequency (%)* 
Cardiac myosin-binding protein C MYBPC3 30-40% 
β-myosin heavy chain MYH7 20-30% 
Cardiac troponin T TNNT2 5-10% 
Cardiac troponin I TNNI3 4-8% 
Regulatory myosin light chain MYL2 2-4% 
Essential myosin light chain MYL3 1-2% 
α tropomyosin TPM1 <1% 
α cardiac actin ACTC1 <1% 
*the frequencies refer to Liew et al. 2017 
HCM is an inherited disorder with an autosomal dominant pattern 
characterised by incomplete penetrance and variable expressivity. The 
variability of the phenotype is due to the causal mutation acting in concert with 
many other genetic and non-genetic influences. Indeed, the primary defect is 
the mutation which affect the structure and function of proteins. Although, the 
phenotype includes also the structural changes and secondary molecular events 
in the myocardium, such as activation of the hypertrophic signalling pathways, 
which occur in response to changes in protein (Figure 9) (Marian and 
Braunwald 2017; Wijnker et al. 2018). 
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Figure 9: hypothetical pathogenesis of hypertrophic cardiomyopathy. The primary 
defect is the mutation in the sarcomere which causes a series of primordial defects. 
These initial defects activate expression of a series of molecular and cellular changes, 
which result in histological and morphological changes in the myocardium, such as 
myocyte hypertrophy and fibrosis. Finally, these changes lead to the clinical 
phenotypes of HCM, such as cardiac arrhythmias and heart failure. 
 
The initial defects, in accord with the diversity of HCM mutations, are also 
diverse. The majority of the HCM mutations are missense mutations that alter 
proteins functions. Missense mutations that impart structural changes in the 
encoded protein may also reduce efficiency of sarcomere assembly. Another 
fraction of the HCM mutations result in premature truncation of the encoded 
proteins because of a gain of a stop codon or a frameshift. These kind of 
mutations commonly abolish protein expression (Marian and Braunwald 
2017). 
 
Such heterogeneity in the expression and incorporation of the mutant proteins 
at the myocyte level might in part explain the variable phenotypic expression 
of HCM.  
Introduction 
 18 
1.2.2 Diagnosis of HCM and the role of genetic testing 
The clinical diagnosis of HCM is based on the presence of left ventricular 
hypertrophy, typically defined by the end-diastolic ventricular septal thickness. 
Although, in the diagnostic criteria, the European Society of Cardiology 
guidelines recommend using a left ventricular wall thickness of ≥15 mm, HCM 
may be diagnosed with a value >13 mm, always occurring in the absence of 
abnormal loading conditions or other secondary causes. The cut point of 13 
mm in adults offers high sensitivity in detecting HCM but has the risk of 
overdiagnosis (Marian and Braunwald 2017). However, in patient with lesser 
degrees of wall thickening (13–14 mm), the diagnosis of HCM requires 
evaluation of other features including family history, non-cardiac symptoms 
and signs, electrocardiogram abnormalities, multimodality cardiac imaging 
and genetic testing (Wijnker et al. 2018). 
 
Up to 60% of patients who meet the HCM diagnostic criteria demonstrate a 
pathogenic sarcomeric mutation on genetic testing. However, the clinical role 
of genetic testing in HCM largely centers on family screening. If a causative 
genetic mutation is identified in a proband with HCM, testing for this mutation 
becomes the preferred method of family screening to facilitate presymptomatic 
diagnosis of family members, clinical surveillance and reproductive advice 
(Geske et al. 2018). It is very important to make a correct classification of 
variants and identification of their pathogenicity and functional relevance for 
an appropriate use of genetic testing in clinical practice. 
 
Due to the increased complexity of analysis and interpretation of genetic tests, 
general guidelines for the interpretation of variants have been published 
(Hershberger et al. 2018). By applying the proposed score, variants can be 
classified into 5 main groups: pathogenic, likely pathogenic, uncertain 
significance (VUS), likely benign and benign. The American College of 
Medical Genetics and Genomics (ACMG) guidelines proposed a process to 
classify mutation composed by six items. The first one is frequency of variants 
in control population in international database (Exome Sequencing Project, 
1000Genome or ExAc). Then, it. is important to know whether the variant has 
been reported previously as associated with disease by control disease 
databases such as Human Gene Mutation Database (HGMD) and ClinVar, or 
sequence databases like NCBI Genome and RefSeqGene. In silico 
pathogenicity scores is the third method proposed for the classification. This 
evaluation can be done using different software (eg, MutationTaster, 
Polyphen2, SIFT, Pmut, ESEfinder) to predict the potential impact of the 
variant on protein structure and/or function. The item number four is the 
evaluation of conservation to determining if the involved nucleotide and amino 
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acid residue are conserved among species and isoforms and if they are located 
in a strategic functional domain. However, this evidence needs careful 
evaluation in the absence of functional study or clinical cosegregation. For that 
reason, the most important items are the cosegregation studies and functional 
studies (Hershberger et al. 2018). 
 
When the different criteria fail to produce assignment of pathogenicity, 
mutations are classifying as VUS. Clinical genetic testing often reports VUS 
with ambiguous and uncertain pathogenicity. VUS may cause difficult clinical 
interpretation and risk-assessment that limit counselling and treatment of 
individuals with unclear genetic predisposition to disease. Therefore, this can 
cause anxiety and stress in asymptomatic individuals and families who are 
found to carry a VUS (Ma et al. 2018). 
 
Genetic test in HCM typically involves a minimum of 8 sarcomere genes 
(MYH7, MYBPC3, TNNT2, TNNI3, TPM1, MYL2, MYL3 and ACTC1), 
although approximately 80% who test positive have causative variants in 
MYBPC3 and MYH7. The mutations occurring in most sarcomeric genes are 
missense-type, with a dominant negative effect resulting in the formation of 
poison peptides, which can be incorporated into the sarcomere. Protein-
truncating variants, which are not incorporated into the sarcomere cause HCM 
by haploinsufficiency. Most MYBPC3 mutations result in frame shifts and 
protein truncations (Sabater-Molina et al. 2018). 
In this thesis, new mutations in the MYBPC3 gene were found and 
characterized.  
1.3 Cardiac Myosin Binding Protein C (cMyBPC) 
G. Offer et al. in 1973 discovered the Myosin Binding Protein C (MyBPC) as 
an impurity in skeletal muscle myosin preparations (Offer et al. 1973). Only 
10 years later the MyBPC was determined and characterized (Yamamoto and 
Moos 1983).  
 
The cardiac isoform (cMyBPC) is exclusively expressed in the heart resulting 
from the MYBPC3 gene composed of 34 coding exons (Carrier et al. 2015). 
cMyBPC is a multi-modular structural protein composed by eight 
immunoglobulin (Ig) and three fibronectin type-3 repeating domains (Figure 
10). cMyBPC differs from its two skeletal isoforms by having a C0 domain, a 
proline-alanine-rich (Pro-Ala) region located between domains C0 and C1, a 
phosphorylatable motif (M-motif), which lies between the C1 and C2 domains, 
and a small insertion within the C5 domain (Sadayappan and De Tombe 2014). 
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Figure 10: model of full-length human cardiac MyBP-C including all domains. The 
four serine phosphorylation sites on the M domain are indicated with asterisks (Nag 
et al. 2017). 
 
cMyBPC is arranged in the C-zone of sarcomeres to run vertically through 
thick and thin filaments. The C-terminal domains of cMyBP-C bind to the light 
meromyosin (LMM) portion of β-myosin heavy chain and to titin. Residues in 
the N-terminus can interact with actin, the S1/S2 junction of myosin heavy 
chain, and the myosin regulatory light chain (RLC). The binding of both actin 
and myosin allows cMyBPC to perform the function as modulator of 
contraction and myofilament rigidity (McNamara et al. 2017). Indeed, the 
absence of cMyBP-C in the effective null mouse models leads to reduced rigor 
cross-bridge-dependent stiffness and thick filament stiffness (Palmer BM et al. 
2011). 
 
Mutations in the MYBPC3 gene represent the 40–50% of all HCM mutations, 
making it the most frequently mutated gene in this disease. Many MYBPC3 
mutations are truncating mutations, including nonsense mutations, nucleotide 
insertions or deletions and RNA splicing mutations that result in frameshifts, 
premature termination codons (PTC) and C-terminal truncated polypeptides. 
The myocardium of patients harboring cMyBPC truncating mutations contains 
less cMyBPC levels, suggesting that haploinsufficiency may be a pathogenic 
mechanism in truncating mutations (Van Dijk et al. 2009; Marston et al. 2009). 
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Indeed, studies with engineered heart tissue provided that contractile function 
is affected when cMyBPC protein levels are below 73% (Wijnker et al. 2018). 
In contrast to truncating mutations, missense mutations lead, in most of the 
cases to stable mutant cMyBPCs that are, at least in part, incorporated into the 
sarcomere and could act as poison polypeptides on the structure and/or 
function of the sarcomere (Carrier et al. 2015). 
HCM mutations are found in all domains of the protein, also in central domains 
that do not interact with myosin or actin. This observation has raised the 
hypothesis that thermodynamic as well as mechanical defects in these domains 
can result in altered function of cMyBPC. Indeed, missense mutations located 
in the central domains (C5-C6-C7) and clinically linked to HCM have been 
identified to interfere with domain folding (Nadvi et al. 2016). Furthermore, 
single-molecule Atomic Force Microscopy (AFM) data on C3 domains shows 
altered mechanical behaviour of mutant proteins (Suay-Corredera et al. 2018). 
1.4 RNA Splicing mechanism 
The removal of introns from pre-mRNA and the joining of exons is a critical 
aspect of gene expression. Introns are removed from primary transcripts by the 
process of RNA splicing, which links together the flanking exons to generate 
functional mature RNA (mRNA) (Papasaikas et al. 2016). The splicing 
reaction takes place in two catalytic steps involving two consecutive trans-
esterification reactions (Figure 11).  
 
Figure 11: chemical mechanism of the RNA splicing reaction. RNA splicing entails 
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two transesterification steps. In the first, the hydroxyl group of an intronic adenosine 
residue of BPS carries out a nucleophilic attack on the phosphate group in the 
exon/intron junction of donor splice site, generating a lariat intermediate. In the 
second step, the free 3’-OH of the 5’-exon attacks the phosphate group in acceptor 
splice site, splicing the two exons together and releasing the intron lariat.  
The exact sites for the trans-esterification reactions are defined by consensus 
sequences, called donor and acceptor sites. The human donor site (5’-splicing 
site) is MAG/GURAGU relative to the exon/intron junction (M is A or C; R is 
purine). In mammals only the first two bases of the intron (GU) are universally 
conserved. The acceptor consensus sequence at the 3’-splice site is defined by 
three separate elements: the branch site (BPS), the polypyrimidine tract (PPT), 
and the intron dinucleotide AG. Together these elements extend 100 
nucleotides into the intron (Buratti et al. 2007).  
 
The splicing reaction takes place in the spliceosome, which is formed by 
several uridine-rich small ribonucleoproteins (UsnRNP), and numerous non- 
snRNP splicing factors. These proteins excise each intron and join exons in the 
correct order through a multitude of RNA-RNA, RNA-protein, and protein-
protein interactions (Baralle and Baralle 2005).  
 
The most common consequences of splicing mutations are skipping of one or 
more exons and/or full intron retention (Tazi et al. 2009, Xiong et al. 2015). 
The mutations that cause splicing alterations involve disruption of native 
splicing sites and/or activation of aberrant 5’-donor and/or 3’-acceptor splice 
sites. 
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2. AIMS 
Hypertrophic cardiomyopathy (HCM) is a genetic disorder, characterized by 
left ventricular hypertrophy in the absence of triggers such as hypertension. 
HCM is the most common inherited cardiovascular disease with an estimated 
prevalence ranging from 1:500 to 1:200. The genetic defects leading to HCM 
usually involve sarcomere disruption. The most frequently mutated HCM gene 
is MYBPC3, encoding cardiac myosin-binding protein C (cMyBPC). 
 
In genetic screens of hereditary disorders, several different types of variants 
can be found: pathogenic mutations, benign polymorphisms and variants of 
uncertain significance (VUS). VUS are an ambiguous category of variants 
whose effects remain unclear, and therefore do not have a clinical value. 
According to the American College of Medical Genetics and Genomics 
(ACMG), in the absence of enough genetic support, functional studies are the 
most important criterion to establish causality of putative disease-causing 
mutations (Hershberger et al. 2018).  
 
In order to understand the pathogenic basis of Hypertrophic Cardiomyopathy, 
to improve characterization of VUS and, finally, to improve molecular 
diagnosis, the evaluation of pathogenic effects by in vitro analysis can be 
helpful for interpretation of variants. In this context, the global aims of this 
project are: 
 
1. Genotyping HCM patients to describe variants in proteins of the 
sarcomere that are associated with HCM. 
 
2. Describing new variants in MYBPC3 that can cause HCM. 
 
3. Integrating cosegregation analysis and functional assessment of 
MYBPC3 variants associated with HCM to refine assignment of 
pathogenicity. 
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3. MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Mammalian Cell culture 
Human embryonic kidney 293 cell line (HEK-293) was used for Minigene 
transfection and RNA analyses. HEK-293 cells were grown as a monolayer in 
Dulbecco’s modified eagle medium supplemented with 10% FBS, 2 mM L-
glutamine and 1% penicillin/streptomycin in a humidified, 5% CO2 
atmosphere at 37°C. 
 
To transfect pMG plasmid, the cells were plated 1 day before transfection onto 
60mm plates at a density of approximately 5x105 cells/plate, in a 4ml of final 
volume of complete medium, in order to be 60-70% confluent the following 
day. 
3.1.2 Bacteria: conservation and manipulation 
Chemically Competent Escherichia coli cells were used for cloning, plasmid 
propagation and protein expression. Competent bacteria were prepared using 
calcium chloride protocol (J. F. Sambrook and D.W. Russell 2001). In short, a 
single colony of E. coli from fresh LB-plate without antibiotics, was pre-
inoculated in 5ml of LB medium and incubated overnight, shaking at 37°C. 
Then, the starter culture of bacteria was inoculated in 100ml of LB medium 
and grown at 37°C. When the optical density at 600 nm (OD600) reached 0.4, 
the cells were immediately put on ice. The bacteria culture was split into four 
parts, centrifuged at 4°C, resuspended in 20ml of ice-cold 50mM CaCl2 each 
and left on ice for at least 40 minutes. Next, the cells were harvested by 
centrifugation at 2000g at 4°C. The pellet was resuspended in about 2 mL of 
ice cold 50mM CaCl2 including 20% glycerol. The suspension was divided in 
200µL aliquot into sterile 1.5 mL tubes and stored at -80°C.  
 
Top10 (Invitrogen™) and BLR (DE3) (Novagen-Merck Millipore) strains of 
E. coli were used in this thesis.  
 
TOP10 are provided at a transformation efficiency of 1×109 cfu/µg 
supercoiled DNA and are ideal for high efficiency cloning and plasmid 
propagation. They allow stable replication of high-copy number plasmids.  
Genotype: F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 recA1 
araD139 Δ(araleu)7697 galU galK rpsL (StrR) endA1 nupG].  
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BLR (DE3) is a recA- derivative of BL21 that improves plasmid monomer 
yields and can help stabilize target plasmids containing repetitive sequences. 
DE3 indicates that the host is a lysogen of λDE3, and therefore carries a 
chromosomal copy of the T7 RNA polymerase gene under control of the 
lacUV5 promoter. Such strains are suitable for production of protein from 
target genes cloned in vectors by induction with Isopropyl β-D-1-
thiogalactopyranoside (IPTG). 
Genotype: F- ompT hsdSB(rB- mB-) gal lac ile dcm Δ(srl-recA)306::Tn10 
(tetR)(DE3). 
3.1.3 Plasmid constructs 
To study the effect of genetic variants on splicing pattern, a minigene construct 
(pMG) was used. This plasmid results from introducing some modifications to 
pEGFP-C3 vector (Amato et al. 2012). The artificial minigene contains the 
human ß-globin gene fragment amplified from genomic DNA of the HEK293 
cell line. A KpnI restriction site was inserted in the middle of the second intron 
of the ß-globin gene and was used to clone genomic DNA fragments for 
splicing studies. The graphic representation of minigene including exon 23 of 
MYBPC3 is shown in Figure 11.  
 
 
Figure 11: graphic representation of the minigene construct with MYBPC3 exon 23 
insert (pMG-exon23). The sequences related to ß-globin include exon 1, exon2, exon 
3 and related intron sequences; whereas for MYBPC3 the exon 23 together with its 
flanking regions were cloned between exon 2 and exon 3 of the ß-globin.  
 
The proteins used for biophysical characterization were engineered and 
expressed using pT7 and pQE80L plasmids, respectively (Figure 12 A, B). 
Expression of proteins from pQE80L results in the addition of a His-tag at the 
N-terminus of the proteins, and a Cys-tag at the C-terminus. In order to avoid 
24/9/2018 rf-cloning.org/cgi-bin/savvy.cgi
http://rf-cloning.org/cgi-bin/savvy.cgi 1/1
pMG­exon23
7386 bp
KpnI 2221
NeoR
EGFP
pBR322 origin
SV40 promoter
f1 origin
TK PA terminator
b­globin
b­globin
exon23
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C-terminal cysteines, pQE80L was modified for the cloning of monomer 
proteins. 
 
Figure 12: plasmids used for proteins engineerin and expression. Graphic 
representation of pT7 (A) and pQE80L (B) including a fragment codified for the 
C4 domain of cMyBPC. 
3.1.4 Primers 
The primers were designed using Primer3 tool (http://primer3.ut.ee/). The 
specification of primers for input PCR template was evaluated with Blat tool 
from UCSC Genome Browser, analysing multisequence alignments. The 
quality was evaluated with OligoAnalyzer Tool from IDT-Integrated DNA 
technologies. 
In the Table 2 the primers used and their sequence are summarized. 
Table 2: List of primers 
Primer name Tail Sequence Primer Sequence (5’-3’) 
MYBPC3-ex3-4 Fw ---------------- CAAGTCCCAAAGGGTCAAGCTC 
MYBPC3-ex6 Rv ---------------- GTGGACACCTCACAGCGGTA 
MYBPC3-ex23 Fw CGGGGTACC CCTGGCTCCCTTCATCCTA 
MYBPC3-ex23 Rv CGGGGTACC CACCCCCAGATCCAAAGAG 
GFP Fwd ---------------- ACGACGGCAACTACAAGACC 
β-globin Rv ---------------- CACACCAGCCACCACTTTC 
MYBPC3-ex15 Fw ---------------- CAAGCGTACCCTGACCATCA 
MYBPC3-ex20-21 Rv ---------------- GGATCTTGGGAGGTTCCTGC 
MYBPC3-ex22-23 Rv ---------------- CACACAGCAGCTTCTTGTCA 
cMyBPC C4 Fw CGCGGATCC AAGCTGGAGGTGTACCAGAGCAT 
cMyBPC C4 Rv ATAGGTACCTTAGCAACAAGATCT CTCCATGAAGTGGAGCTTGGCTG 
cMyBPC C4 I603M Fw ---------------- GTCCACAAACTGACCATGGACGA
CGTCACACCT 
24/9/2018 rf-cloning.org/cgi-bin/savvy.cgi
http://rf-cloning.org/cgi-bin/savvy.cgi 1/1
pT7
2899 bp
KpnI 119
BglII 104
BamHI 98
AmpR
pBR322 origin
f1 origin
lac promoter
AmpR promoter
24/9/2018 rf-cloning.org/cgi-bin/savvy.cgi
http://rf-cloning.org/cgi-bin/savvy.cgi 1/1
pQE80L­domainC4
5018 bp
KpnI 429
BglII 420
BamHI 144
lacIq Repressor
AmpR
ChloramR
pBR322 origin
domainC4
A B
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The primers used for splicing analyses using mRNA from peripheral blood are 
designed to recognise exon sequences of MYBPC3. The forward primer 
(MYBPC3-ex3-4 Fw) anneals with the end region of exon 3 and initial 
sequence of exon 4. The MYBPC3-ex6 Rv recognises the exon 6 of MYBPC3. 
MYBPC3-ex23 Fw and MYBPC3-ex23 Rv were used to generate the insert of 
pMG vector. These primers carried a tail region that includes the sequence of 
KpnI restriction site (GGTACC) The oligonucleotides GFP Fwd and β-globin 
Rv were designed to amplify by RT-PCR and sequence the mRNA product in 
Minigene experiments, and anneal with the GFP sequence and the exon 3 of β-
globin, respectively. The MYBPC3-ex15 Fw, MYBPC3-ex20-21 Rv and 
MYBPC3-ex22-23 Rv oligonucleotides anneal with exon 15 of MYBPC3, the 
region between exon 20 and exon 21, and the sequence straddling exons 22 
and 23, respectively. To generate cDNA cloning for the C4 domain, the 
primers cMyBPC C4 Fw and cMyBPC C4 Rv were used. The Forward primer 
is complementary to exon 18 of MYBPC3 and carries a tail region with one 
BamHI restriction site (GGATCC). The reverse primer carries a tail region 
including KpnI and BglII (AGATCT) restriction sites, codons introducing two 
extra cysteines (GCAACA, the reverse and complentary sequence of TGT 
TGC) and a stop codon (TTA, reverse and complementary of TAA). The 
sequence of cMyBPC C4 Rv anneals with exon 19 of MYBPC3. Finally, the 
cMyBPC C4 I603M Fw was designed to introduce the mutation I603M in the 
domain C4. 
 
3.2 Methods 
3.2.1 General Molecular Biology 
Standard molecular biology techniques (digestion, ligation, agarose 
electrophoresis, PCR, etc.) were performed according to standard protocols (J. 
F. Sambrook and D.W. Russell 2001). 
3.2.2 Screening of HCM patients 
Genomic DNA was isolated from peripheral whole blood with the Nucleon 
BACC2 kit (GE Healthcare, Life Sciences, Little Chalfont Buckinghamshire, 
UK). All coding exons, and 5′ and 3′ UTRs of genes involved in inherited 
cardiomyopathies associated to sudden death were amplified by PCR and 
analysed by automatic sequencing using previously reported protocols (F. 
Girolami et al. 2018). Thirty out of 249 patients were analysed using Next 
Generation Sequencing methodology for a large number of target genes. 
Informed consent to perform genetic analysis was obtained from patients 
according to the Helsinki Declaration. The nomenclatures are indicated 
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following HGVS recommendations for the descriptions of sequence variants 
(den Dunnen et al. 2016). 
3.2.3 Bioinformatics assessment of mutations 
Alamut software (Alamut® Visual, Interactive Biosoftware)was used for in 
silico prediction of splice-affecting nucleotide variants (Houdayer 2011). 
Genomic sequences (WT and mutant) were processed by this predictor 
software using five splicing prediction tools (SpliceSiteFinder-like, 
MaxEntScan, Neural Network Splice, GeneSplicer, and Human Splicing 
Finder). Each tool is based on different algorithms: SpliceSiteFinder-like uses 
position weight matrices computed from a set of human constitutive 
exon/intron junctions for donor and acceptor sites; MaxEntScan and 
NNPLICE are based on the Maximum Entropy principle and neural networks, 
respectively. GeneSplicer combines several splice site detection techniques, 
namely Markov models; and HSF is based on position weight matrices with 
some position-dependent logic. 
Missense mutation at the protein level were evaluated with three independent 
bioinformatics tools which predict possible impact of amino acid substitutions 
on the structure and function of the protein (PolyPhen-2, SIFT, Provean). 
PolyPhen-2 (Polymorphism Phenotyping v2) evaluates the impact of amino 
acid allelic variants via analysis of multiple sequence alignments and protein 
3D-structures (Adzhubei et al. 2015). SIFT (Sorting Intolerant From Tolerant) 
presumes that important amino acids will be conserved in the protein family, 
so changes at well-conserved positions tend to be predicted as deleterious (Ng 
and Henikoff 2003). PROVEAN (Protein Variation Effect Analyzer) is a 
software tool which predicts whether an amino acid substitution has an impact 
on the biological function of a protein using pairwise sequence alignment 
scores (Choi and Chan 2015).  
3.2.4 Homology modelling for protein structure 
For modelling of cMyBPC’s C4 domain, the protein sequence Q14896 from 
the UniProt database was used. The structure was modelled using I-TASSER 
tool using slow-MyBPC (2YUZ PDB) as template. I-TASSER (Iterative 
Threading ASSEmbly Refinement) is a hierarchical approach to protein 
structure and function prediction (Zhang 2008). It first identifies structural 
templates from the PDB by the multiple threading approach LOMETS. Then, 
full-length atomic models are constructed by iterative template fragment 
assembly simulations. PyMol software was used for molecular representation 
(DeLano 2002). 
Materials and Methods 
 32 
3.2.5 Splicing Analysis of mRNA from peripheral blood  
Total RNA was extracted from 5-10 mL of patients’ peripheral blood. Five 
volumes of 0.2% NaCl was added in order to lyse red blood cells and isolate a 
pellet that includes lymphocyte cells. Then, the RNA was isolated from this 
peleet using Trizol Reagent (Thermo Fischer Scientific, Waltham, MA, USA). 
RNA retro-transcription was performed by SuperScript VILO (Life 
Technologies) starting from 1µg of total RNA and using random primers. The 
cDNA obtained was amplified using specific consecutive-exon-spanning 
primers (Table 2). The same primers were used for sequencing of PCR 
fragment. Sequence was aligned with reference and analysed with CodonCode 
Aligner software (CodonCode Corporation, Dedham, MA, USA). 
3.2.6 RNA Splicing Analysis by Minigene strategy	
3.2.6.1 Insert Generation  
Genomic DNA of patient carrying MYBPC3-c.2308+3G>C mutation was 
isolated from peripheral whole blood with the Nucleon BACC2 kit (GE 
Healthcare, Life Sciences, Little Chalfont Buckinghamshire, UK). The 
genomic regions affected by non-coding mutations were amplified by PCR 
using PCR Master Mix (Promega, Madison, WI, USA). The sizes of inserts 
obtained by PCR were approximately 1000 base pairs. The PCR amplicons 
contained the exon 23 and the 5′ and 3′ intronic flanking regions. The primers 
contained a KpnI restriction sequence at the 5′ terminus (Table 2). The PCR 
product was cloned in TOPO TA (Invitrogen™) amplification vector. The 
resulting E. coli colonies grown in LB plate with Ampicilin were used for mini-
prep purification of plasmid DNA (QUIAGEN). The TOPO TA positive 
plasmids were Sanger-sequenced for insert verification. Since the patient was 
heterozygote both WT and 2308+3G>C fragments were obtained in the same 
cloning.  
 
3.2.6.2. Minigene Plasmid Construction, Expression, and Transcript 
Analysis  
The TOPO TA WT and mutated vectors and pMGgene vector were digested 
with the KpnI restriction enzyme (Gaildrat et al. 2010; Amato et al. 2012). The 
open pMGene vector was then dephosphorylated. The digested inserts were 
then cloned into the pMGene vector using the LigaFast Rapid DNA Ligation 
System (Promega). Top10 E. coli competent cells were transformed and grown 
in selective LB plate with Kanamicin. All clones were sequenced, and the WT 
and mutated forms were selected for expression experiments. 
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HEK-293 cells were transiently transfected with FuGene®HD (Promega) 
according to the manufacturer’s instructions, using 2µg of WT or mutated 
pMGene and 3µl of FuGene®HD transfection reagent in 100µl absolute 
DMEM medium without FBS. After six hours the medium of cells was 
substituted with complete DMEM. Forty-eight hours after transfection cells 
were collected and RNA was extracted by Trizol Reagent (Life Technologies). 
RNA retrotranscription was performed by SuperScript VILO (Life 
Technologies) starting from 1µg of total RNA and using random primers. The 
cDNA obtained was amplified with GFP Fw and β-globin Rv primers. Since 
the forward primer annealed in the GFP-coding region, only located in the 
transcripts derived from the plasmid construct, the PCR did not select 
endogenous β-globin or MYBPC3 transcripts. The amplification products 
were analysed by Sanger sequencing. 
3.2.7 Biophysical characterization of proteins 
3.2.7.1 Protein expression and purification 
The C4 domain sequence used to generate recombinant proteins and 
heteropolyproteins, corresponds to entry Q14896 (MYBPC3_HUMAN) of the 
UniProt databases. 
 
The cDNA fragment including exons 18 and exon 19 of MYBPC3, was 
amplified from cardiac RNA with cMyBPC C4 Fw and cMyBPC C4 Rv 
oligonucleotides (see primers section). The primers were designed to clone just 
the coding sequence and to introduce BamHI, KpnI and BglII restriction sites. 
The PCR fragment was ligated into pT7 vector after digestion with BamHI and 
KpnI. Polymerase chain reaction-based site-directed mutagenesis was used 
with cMyBPC C4 I603M Fw internal primer to introduce the mutation I603M.  
Production of monomeric proteins for thermodynamic analysis. The pT7-
C4 WT and pT7-C4 I603M were digested using BamHI and BglII and the 
fragments were cloned into modified pQE80L expression vector. Expression 
plasmids were verified by Sanger sequencing. The resulting constructs, 
denoted as His6-C4 WT and His6-C4 I603M, encode the WT C4 domain and 
C4 I603M of cMyBP-C with an N- terminal hexahistidine affinity tag. Full 
protein sequences are reported in Table 3. 
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Table 3: amino acid sequences of C4 monomers 
Protein Sequence # aa Extinction 
coefficients 
cMyBPC C4 
WT  
MRGSHHHHHHGSKLEVYQSIADLMVG
AKDQAVFKCEVSDENVRGVWLKNGK
ELVPDSRIKVSHIGRVHKLTIDDVTPAD
EADYSFVPEGFACNLSAKLHFMERS 
104 0.736 g/L 
    
cMyBPC C4 
I603M  
MRGSHHHHHHGSKLEVYQSIADLMVG
AKDQAVFKCEVSDENVRGVWLKNGK
ELVPDSRIKVSHIGRVHKLTMDDVTPA
DEADYSFVPEGFACNLSAKLHFMERS 
104 0.724 g/L 
 
Proteins were expressed in BLR (DE3) E. coli strain. Fresh cultures were 
grown at 37 °C to an OD600 of 0.6-1.0 and induced with 1mM IPTG. After 3 
hours of induction at 37ºC and 250 rpm, C4 WT cultures were harvested. In 
the case of the C4 I603M, optimal expression was obtained by induction 
overnight at 14°C and 250 rpm. Cells were lysed by a combination of tip 
sonication and passes through a French Press. Proteins were purified from the 
soluble fraction using Ni-NTA agarose chromatography (Qiagen) with a 
column volume of 3 mL and pre-equilibrated with phosphate buffer (50 mM 
sodium phosphate pH 7 and 300 mM NaCl) supplemented with 10 mM DTT. 
Elution was performed in two steps with increasing imidazole concentration 
(from 20mM to 250mM). Further purification was achieved by size-exclusion 
chromatography in an AKTA Pure 25L system using a Superdex 200 Increase 
10/300 GL column (GE Healthcare). The proteins were eluted in phosphate 
buffer, which is also the buffer used in circular dichroism (CD) and differential 
scanning calorimetry (DSC) experiments. The eluent was monitored by 
ultraviolet absorbance at 280nm. Concentrations of purified proteins were 
determined using theoretical extinction coefficients as estimated by the 
ProtParam tool (Table 3). Purity of samples was evaluated using SDS-PAGE. 
Production of polyproteins for single-molecule experiments. To analyse the 
mechanical stability of C4 domain, heteropolyproteins were generated with 
two different markers, Protein-L and Sumo1 (Sadler et al. 2009; Kotamarthi et 
al. 2013)(Figure 13). Starting from pT7-C4 WT and pT-C4 I603M, the 
heteropolyproteins were generated with directional DNA concatemerization 
by self-ligation of the sticky ends of BamHI and BglI restriction sites (Alegre-
Cebollada et al. 2010). Final cDNAs were inserted in the pQE80L expression 
plasmid using BamHI and KpnI and the resulting plasmids were verified by 
Sanger sequencing.  
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C4domain  Protein-L  Sumo1 
 
Figure 13: schematic representations of (C4-L)4 and (C4-Sumo1)4 heteropolyproteins. 
 
The heteropolyproteins were expressed in BLR (DE3) E. coli cells. Fresh 
cultures (OD600 = 0.6-1.0) were induced with 1mM IPTG for 3 hours at 37ºC 
and at 250 rpm. Purification was achieved following the same procedure as for 
monomers (see above). The buffer used for the size-exclusion chromatography 
was 10 mM Hepes, pH 7.2, 150 mM NaCl, 1 mM EDTA, which is the same 
one used in AFM experiments. The eluent was monitored by the ultraviolet 
absorbance at 280nm. Then, the proteins fractions concentrations were 
determined using predicted extinction coefficients (ProtParam) and their purity 
was evaluated using SDS-PAGE gels. 
3.2.7.2 Circular Dichroism (CD) 
CD is defined as the unequal absorption of left-handed and right-handed 
circularly polarized light. The difference in absorbance of clockwise (ER) and 
counterclockwise (EL) polarized light is reported in units of ΔE, or in degrees 
ellipticity, defined as the angle whose tangent is the ratio of the minor to the 
major axis of the ellipse (Greenfield 2006). In particular, the CD data are 
reported as molar ellipticity	 𝜃  in units of 𝑑𝑒𝑔 ∙ 𝑐𝑚) ∙ 𝑑𝑚𝑜𝑙,-.  
CD spectra of cMyBPC domain C4 were collected for both the WT and I603M 
C4 samples with a Jasco-810 spectropolarimeter. The temperature was 
controlled using a Peltier thermoelectric system.  
 
Purified proteins in phosphate buffer (20 mM sodium phosphate pH 6.5 and 
50 mM NaCl) were loaded into a 0.1cm or 1cm path-length quartz cuvettes for 
data collection from far-UV (195-250nm) and near-UV (250-350nm) 
respectively. The proteins were analysed at concentration of 0.3 and 1 mg/mL 
for far-UV and near-UV respectively. Spectra were collected for the protein 
samples and buffer control at 25°C and 85°C with four accumulations of data. 
The parameters set for CD measurements are summarised in Table 4. The 
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buffer baseline spectrum was subtracted from each protein spectrum at each 
corresponding temperature to correct for the background signal. 
 
Table 4: parameters used to measure the spectrum collection from far-UV (195-
250nm) and near-UV (250-350nm) 
 
 
 
 
 
 
Thermal denaturation analyses were carried out collecting the variations of 
ellipticity at 205nm and 230nm as a function of temperature (25°C-85°C). The 
thermal renaturation was also analysed with a temperature ramp-down (85°C-
25°C). The spectrum measurement parameters are summarised in Table 5.  
Table 5: parameters of thermal denaturation analysed at 215nm or 230nm 
Variable Temperature measurement 
Wavelength 215/230nm 
Start temperature 25ºC 
End temperature 85ºC 
Data pitch 0.5 ºC 
Delay Time 0 
Temperature Slope 30°C/h 
 
Protein unfolding was plotted versus temperature and the data points were fit 
with a Boltzmann sigmoidal curve using Igor Pro software to obtain midpoint 
unfolding temperatures (Tm) for WT and I603M C4 domain. The changes in 
CD as a function of temperature, at characteristic wavelengths, can be used to 
determine the van't Hoff enthalpy (ΔHv) of unfolding (Greenfield 2007).  
 
To fit the change of CD at a single wavelength as a function of temperature, 
the Gibbs-Helmholtz equation was used considering a two-state process: 
ΔG= ΔH (1-T/Tm)- ΔCp((Tm-T)+Tln(T/Tm)) 
 
Spectrum Measurement  
Start wavelength 250/350nm 
End wavelength 195/250nm 
Data pitch 0.2nm 
Scanning mode continuous 
Scanning speed 50nm/min 
response 1sec 
Band width 1 
Accumulation 4 
Materials and Methods 
 37 
considering that 
K=exp(-ΔG/(RT)) 
 
and 
α=K/(1+K) 
 
θt=α(θF-θU)+θU 
Where α is the fraction unfolded protein, K is unfolding constant, T is the 
absolute temperature (Kelvin) and R is the Gas constant (1.98 cal/K/mol). 
ΔCp is the change in heat capacity going from the folded to the unfolded state. 
We considered ΔCp = 0.  
3.2.7.3 Differential scanning calorimetry (DSC) 
DSC is a powerful technique to characterize temperature-induced 
conformational changes in proteins and other biological macromolecules 
(Cooper and Johnson 1994). Calorimetric measurements were performed using 
a Microcal VP-DSC differential scanning calorimeter with 0.5 mL cells. 
Experiments were done increasing temperature from 25°C to 85°C at a rate of 
0.5°C/min, using 0.085 mM (1 mg/mL) protein concentration in 20 mM 
sodium phosphate pH 6.5, 50 mM NaCl. The reversibility of the thermal 
transitions was assessed by reheating of the sample immediately after cooling 
from the previous scan, using the same rate of temperature change. The 
calorimetric traces were corrected for the instrumental background by 
subtracting a scan with buffer in both cells. The temperature dependence of the 
excess heat capacity was further analysed and plotted using Origin software 
(MicroCal, Northampton, MA). The thermal stability of the proteins was 
described by its Tm, and the calorimetric enthalpy (ΔHcal), which was 
calculated as the area under the excess heat capacity function. The van’t Hoff 
enthalpy (ΔHv) associated with DSC thermograms was determined by a two-
state fit of the thermograms. 
𝐶/ = 𝐶/1 +	 𝐾4	∆𝐶/41 + 𝐾4 + 𝐾4	∆𝐻8)1 + 𝐾4 )𝑅𝑇)  
where CpN is the molar heat capacity of the totally folded state and ∆CpA is the 
change in heat capacity for unfolding the A domain (DSC Data Analysis in 
Origin®-Tutorial Guide). 
The Gibbs free energy change (∆G) was then calculated at any temperature 
using three experimental parameters: Tm, enthalpy change at TM (∆H(Tm)) and 
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heat capacity change at Tm (∆Cp). Using this parameters, the ∆G was derived 
from the above equation: 
 
The derivation assumes a reversible two-state transition and also assumes ∆Cp 
is independent of temperature (DSC Data Analysis in Origin®-Tutorial 
Guide). The ∆G was derivate for C4 WT and C4 I603M considering ∆Cp = 0.  
 
3.2.7.4 Single-molecule Atomic Force Microscopy (AFM)	
Single-molecule AFM measurements were obtained in a commercial force-
clamp AFS (Luigs & Neumann) following established protocols (Popa et al. 
2013). In AFM experiments, we were able to stretch single polyprotein 
molecules tethered between a gold-coated surface and the tip of an AFM 
cantilever probe. 
 
Forces between the tip and the sample lead to a deflection of the cantilever 
according to Hooke's law: 
𝐹 𝑝𝑁 = Δ𝑥 𝑛𝑚 𝑘BC 𝑝𝑁𝑛𝑚  
Where ∆x is the displacement of cantilever and ksc the spring constant. 
The cantilever spring constant is described as follows: 
𝑘BC = 𝑘D𝑇𝑆) 𝑥)  
Where kb is Boltzmann’s constant, T is the absolute temperature (K), S is the 
contact slope or deflection sensitivity (nm/V) and ‹x2› is the mean squared 
displacement of cantilever (nm). 
 
The cantilevers were calibrated before measurement according to the thermal 
fluctuations method in which the mean squared displacement of cantilever ‹x2› 
was determined when the cantilever is positioned far from the gold-coated 
surface (Hutter and Bechhoefer 1993). 
During an AFM experiment, ∆x is calculated as changes in the A-B signal of 
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VII. Using DSC data to calculate ∆G at temperature T by extrapolating from the 
midpoint TM 
 
From analysis of a DSC scan on a protein, three experimental parameters for the unfolding transition are 
obtained.  These include  
 
midpoint = TM 
     Enthalpy change at TM = ∆H(TM) 
     Heat capacity change at TM = ∆Cp 
 
Using these three experimental parameters, the Gibbs free energy change ∆G may then be obtained at any temperature 
T as indicated below.  The derivation assumes a reversible two-state transition and also assumes ∆Cp is independent of 
temperature. 
 
Derivation: 
 
Starting from well-known thermodynamic relation 
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Integrating the above equation from TM (where ∆G=0) to another temperature T then gives 
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Once the temperature T is assigned, all other parameters in the above equation are known except ∆G which can then 
be calculated. 
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photodiode. Then, the signal in volts (V) coming from the photodiode, is 
converted in length units (nm) the using following equation: 
 𝑥 𝑛𝑚 = 𝑆 𝑛𝑚𝑉 𝐴 − 𝐵 (𝑉) 
Silicon nitride MLCT-C cantilevers were used with a 60-nm gold back side 
coating (Bruker). Typical spring constant values ranged between 15 and 20 
pN/nm. 
 
In the classical force-extension mode (FX) the traces are recorded at constant 
velocity of piezo retraction. In this mode, the cantilever measures the force 
response of the protein as its end-to-end length changes. Alternatively, in 
force-clamp mode the position of the piezo is adjusted such as the cantilever 
deflection is maintained at a given set-point force by a proportional–integral–
derivative (PID) controller which adjusts the position of the piezo (Schlierf et 
al. 2004). 
 
A small aliquot (2µL) of the purified protein is deposited directly into the 
buffer in the fluid chamber. The cantilever is brought in contact to the surface 
for 1s at 500-1500 pN to favor formation of single-molecule tethers. Then, the 
surface is retracted to achieve the set point force. If a single-molecule tether is 
formed, the force is increased linearly at 10 pN/s for 20 s while the length of 
the polyprotein is measured. Under this condition, protein unfolding events are 
detected as step increases in the length of the heteropolyproteins. Under force 
clamp, the length of protein-L unfolding steps is 16 ± 1 nm, whereas Sumo1 
unfoldings produce 20 ± 1 nm unfolding steps (Pimenta-Lopes et al. 2018). To 
fingerprint the C4 domain, all traces that contain at least two events of the same 
size were analysed and represented as histograms. 
 
In the data analysis, traces in FX mode were fitted to the worm-like chain 
(WLC) model of polymer elasticity (Bustamante et al. 1994): 
𝐹 𝑥 = 𝑘B𝑇𝑝 	 14 1 − 𝑥𝐿C ,) − 14 + 𝑥𝐿C  
where p and Lc are the persistence length and contour length, respectively, kB 
is Boltzmann’s constant and T is absolute temperature.  
 
Data acquisition and analysis was performed using custom software written 
in Igor Pro (Wavemetrics). 
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To estimate the initial extension of the polyproteins only reproducible traces 
with four protein L unfolding events were analysed. The force-extension traces 
were fitted with the WLC model to calculate the contour lenght up to the first 
unfolding peak. The expected initial extension was calculated considering C4 
was unfolded or folded. In the first case the expected initial extension results 
by the sum of the length of four folded L modules (4 x 3 nm), the handles and 
linkers included in polyproteins (28 amino acids x 0.4 nm/amino acid) and the 
length of the extended C4 domain (4 x 90 amino acids x 0.4 nm/amino acid) 
for a total length of 167.2 nm. In contrast, if C4 remained folded, the initial 
extension would correspond to the extension of the folded L domains, the 
handles and linkers and the folded C4 (4 x 4.1nm) for a total length of 39.6 
nm. The length of each folded domain (L proteins and C4 domains) was 
obtained measuring the distance between the α-carbons of the first amino acid 
and the last amino acid in the high resolution structures of the domains.  
 
The AFM tip picks the protein at random locations, so the number of peaks 
observed depend on the number of modules contained in the segment that is 
stretched by the AFM. Hence, the full extension of the heteropolyprotein has 
to be evaluated from traces with all four unfolding events of protein L. 
However, if the cantilever picked up the second domain of protein 
corresponding to L, the unfolding traces would not include one domain C4 and 
flanking linkers, a scenario that was taken into account to calculate a range of 
predicted initial extensions. Specifically, if the first C4 domain is not picked 
up by the cantilever, the initial extension would be 29.9 nm for C4 folded and 
125.6 nm for C4 unfolded. 
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4. RESULTS 
4.1 The spectrum of sarcomeric mutations in HCM patients 
A large genetic screening of about 249 patients affected by hypertrophic 
cardiomyopathy was performed. No mutation was found in 38% of the 
patients, while the rest carried double o single mutations in genes coding for 
sarcomeric proteins. Most of them are localised in MYH7 (33%) and MYBPC3 
(41%), in agreement with literature data (Figure 14) (Burke et al. 2016; Liew 
et al. 2017). 
 
Figure 14: distribution of mutations in genes coding for sarcomeric proteins identified 
in genetic screening of HCM patients. 
The focus of this thesis was MYBPC3, the most frequently mutated gene in 
HCM. The principal mutations of MYBPC3 related to Hypertrophic 
Cardiomyopathy include missense and truncating mutations (Marston et al. 
2012; Mohamed et al. 2017). Among those patients harboring mutations in 
MYBPC in our cohort, 57% of them have truncating mutations compared to 
43% of missense mutations. Protein truncation can result from frameshifts, 
premature termination codons (PTC) or mutations causing splicing alterations. 
In our HCM population, these possibilities occur with different frequencies: 
25% are frameshifts, 7% are non-sense mutation, and 25% of intronic mutation 
that cause splicing alterations (Table 6). Most of the mutations found had 
already being described as pathogenic. The following mutations have not been 
reported before: p.T33RfsX15, p.R502Rfs, p.G897AfsX159, IVS4-2A>C and 
41%
33%
3%
2%
2% 7%
8% 4%
MYBPC3
MYH7
MYL2
MYL3
TNNI3
TNNT2
double mutations
others
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IVS23+3G>C. Most of the identified missense mutations had been also already 
associated with HCM, and some of them were functionally characterised. 
However, mutations p.I603M and p.T705K had not been reported before 
(Table 7). 
 
Table 6: MYBPC3 Truncated mutations identified in genetic screening 
TRUNCATED MUTATIONS 
splicing non sense frameshift 
IVS4-2 A>C  p.Q1012X p.T33RfsX15 
IVS9-1 G>C p.Q1259X (3) p.F305Pfs 
IVS11-9 G>A (4) p.W1214X p.R502Rfs 
IVS23-2 A>G (6)  p.M632Rfs (3) 
IVS23+3 G>C  p.G897AfsX159 
IVS32+2 T>A (6)  p.G1206Vfs 
  p.K1065QfsX12 (11) 
(Number in parenthesis are the number of patients with the corresponded mutation) 
 
Table 7: MYBPC3 missense mutations identified in genetic screening 
MISSENSE MUTATIONS 
p.P102L p.G507R 
p.G148R (2) p.R574W 
p.V178M p.R597Q 
p.V189I p.R597W 
p.S217G (3) p.I603M 
p.E258K (2) p.E619K (2) 
p.P371R (4) p.T705K 
p.E441K p.R810H (2) 
p.R495G p.R820Q 
p.R495Q p.A848E 
p.R502W p.V906G 
p.R502Q p.Y1172C 
(Numbers in parenthesis are the number of patients with the 
corresponded mutation) 
In figure 15, the distribution of mutations along the different domains of 
cMyBPC protein is shown. The sixteen different truncating mutations were 
spread throughout all domains of protein. The terminal domains, which are 
interactors of actin, myosin and titin (Harris et al. 2011), were slightly enriched 
in truncating mutations. In contrast, the majority of missense mutations affect 
the central region of cMyBPC between domains C3 and C7. Indeed, among 
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twenty-five different missense mutations, ten map to the C3 and C4 domains, 
with no sarcomeric known interactor.  
 
Figure 15: mutations of cMyBPC found in a genetic screen of 249 HCM patients. 
Missense (bottom) and truncating (top) mutations in cMyBPC are shown according to 
the affected domain. The number of patients with the corresponding mutation is 
indicated between parentheses.  
4.2 Functional characterization of variants affecting splicing 
The genetic screening highlighted several frameshift, and PTC variants in the 
MYBPC3 gene. The new variants p.T33RfsX15, p.R502Rfs, p.G897AfsX159 
result in cMyBPC protein truncation. The premature truncation of the 
polypeptide probably results in lower protein levels, leading to cMyBPC 
haploinsufficiency and development of HCM in these variants (Van Dijk et al. 
2009; Harris et al. 2011; Marston et al. 2012).  
 
The pathogenicity of intronic variants is much more difficult to deduce without 
functional characterization. Therefore, a detailed functional study of new non-
coding variants, IVS4-2 A>C (c.506-2 A>C) and IVS23+3G>C (c.2308+3 
G>C), was developed.  
The intronic variants were identified in two independent patients affected by 
HCM. Both variants were found in heterozygous pattern without mutations in 
other genes screened in these patients.  
 
During this work, the MYBPC3 c.506-2 A>C variant has been reported as 
disease-associated but no functional validation was provided. The variant co-
segregates with disease, as showed in the family pedigree (figure 16). Although 
no HCM phenotype was clinically evident in two subjects who carry the 
mutation, all affected patient are positive in genetic screening for c.506-2 A>C. 
The MYBPC3 c.2308+3 G>C, is a new intronic variant not previously 
associated to HCM phenotype. Although no family screening was requested 
and the patient analysed presented borderline clinical evidence of the disease, 
the mutation was however selected for functional characterization.  
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Figure 16: pedigree of HCM family with the c.506-2 A>C variant. Open symbols 
represent subjects with a negative phenotype. Black symbols represent clinically 
affected subjects. Circles with solid centers indicate unaffected female mutation 
carriers. The diagonal line indicates a deceased family member. The arrows indicate 
the proband. The ages of subjects are reported in brackets. N.A.: not analysed; WT: 
wild type  
Both variants were located in a consensus region known as acceptor or donor 
splice sites. In particular, c.506-2A>C targets a consensus sequence of intron 
4 acceptor splice site of the MYBPC3 gene. c.2308+3 G>C involves the donor 
splice site of intron 23. Hence, the location of both mutations suggest that these 
variants may alter correct RNA splicing. 
4.2.1 In silico studies to predict splicing changes  
The pathomechanism of intronic mutations is, in most cases, due to defects in 
splicing process (Salman et al. 2018). The splicing is the editing of pre-mRNA 
transcript into a mature messenger RNA (mRNA) in which introns are 
removed and exons are ligated (see section 1.4 in the introduction). The 
mechanism involves the recognition of donor and acceptor splicing sites. 
Mutations in these specific sequences block canonical splicing, resulting in 
aberrant mRNAs (Baralle and Baralle 2005; Buratti et al. 2007).  
 
In order to verify whether the two mutations result in aberrant alternative 
splicing of MYBPC3, in silico analysis by five different algorithms were 
performed using Alamut® Visual software. 
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The analyses of MYBPC3-c.506-2A>C mutation showed a severe impact on 
splicing process with completely loss of the natural acceptor splice site 
predicted by all five algorithms with a maximum score. Although with a low 
probability, three algorithms (SSF, MaxEnt and GeneSplicer) also identified a 
cryptic splice site at position c.513 of MYBPC3 exon 5, i.e. 7 nucleotide 
upstream of the native splicing site. The final result of Alamut elaboration is 
the high probability of exon 5 skipping (figure 17A). 
 
For MYBPC3-c.2308+3G>C mutation, MaxEnt and NN Splice algorithms of 
the Alamut software predicted a consistent alteration of the natural donor site. 
The algorithms showed an close to 50% of reduction and a total site loss, 
respectively. The other three algorithms also predicted a donor site alteration, 
but the percentage of variation induced by the mutation was not as high (SSF 
≥ −7.1%, GeneSplicer ≥ −32.8%; HSF ≥ −8%). No indications of formation of 
a new splicing site were predicted for this mutation (figure 17B).  
 
Figure 17: prediction of splicing alterations using Alamut software. The histograms 
represent the score given by the different prediction algorithms for a splicing site loss 
(left) and for the appearance of a new acceptor site (right). (A) Predictions for the 
c.506-2 A>C variant. (B) Prediction for c.2308+3 G>C variant. The evaluations were 
carried out with five algorithms of splicing prediction: SSF (SpliceSiteFinder-like), 
MaxEnt, NNSPLICE (Neural Network Splice), GeneSplicer and HSF (Human 
Splicing Finder). 
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4.2.2 Experimental validation of splicing pathomechanism 
RNA splicing analyses for these variants were preferentially carried out using 
peripheral blood. In the absence of samples, splicing analyses using the 
minigene assay were performed.  
 
The total RNA of the HCM patient carrying mutation c.506-2A>C was 
extracted from leukocyte fractions of peripheral blood and was retrotranscribed 
by RT-PCR using random primers. The region spanning from exon 3 to exon 
6 of MYBPC3 was amplified by specific primers and the sequence was 
analysed. A healthy subject without MYBPC3 mutations was also analysed as 
a control. The RT-PCR amplified a band of the expected size (334bp) in both 
individuals. The sequence corresponding to the PCR product of the HCM 
patient showed both a normal and an aberrant splicing of mRNA accordingly 
with the heterozygous pattern. The normal mRNA carried the sequence of exon 
4 followed by normal exon 5. Instead, the aberrant form showed a truncated 
exon 5 with a seven nucleotide loss (figure 18). This RNA alteration results in 
the substitution of glycine 169 with an alanine and a subsequent frame-shift 
and generation of a premature stop codon (MYBPC3-G169AfsX14). 
 
Figure 18: Effect of the c.506-2A>C mutation on the splicing of exon 5. (Left) 
Electrophoresis of the exon3-exon6 RT-PCR fragment of MYBPC3 from mRNA of 
healthy subject (WT) and patient. Lane 1: Marker IX (Roche Diagnostics); Lane 2: 
Control WT; Lane 3: c.506-2A>C mutation. (Right) Electropherograms obtained from 
Sanger sequencing of the fragments; black, red, green and blue peaks represent G, T, 
A, and C. The electropherograms capture the end of exon 4 (highlighted in green) and 
the start sequence of exon 5 of MYBPC3 cDNA (highlighted in pink), or a truncated 
mRNA in the case of the HCM patient carrying the mutation c.506-2A>C. 
 
 Results 
 49 
Since no cardiac biopsies or fresh peripheral blood sample of HCM patients 
carrying mutation c.2308+3G>C were available, a minigene system was used 
to verify the results obtained with the Alamut predictor software. A splicing 
minigene assay is based on an expression plasmid (pMG) containing the 
human β-globin gene (HBB), from the starting codon to the stop codon 
(including introns), and the GFP coding sequence fused with exon 1 of HBB. 
The genomic region containing the mutation (including the whole exon and the 
5’ and 3’ intronic flanking regions) is inserted in pMG after amplification from 
genomic DNA. In particular, the insert for the analyses of c.2308+3G>C 
contained exon 23. The pMG-MYBPC3-WT and pMG-MYBPC3-
2308+3G>C plasmids were transfected in HEK293 cells, the total RNA was 
extracted, retrotranscribed and sequenced. The analysis of the RNA obtained 
from the minigene system for c.2308+3G>C showed generation of two 
transcripts (normal and alternative) in pMG-MYBPC3-WT and only one 
(alternative) in pMG-MYBPC3-2308+3G>C (figure 19). Sanger sequencing 
shows that the alternative transcript arises from the skipping of MYBPC3’s 
exon 23. It is unclear whether this non-canonical splicing site also occurs in 
wild-type human subjects. However, results in figure 19 show that the acceptor 
site leading to inclusion of exon 23 in the mRNA of cMyPBC is weakened by 
the mutation 2308+3G>C, pointing towards a pathogenic status of the 
mutation. If exon 23 is skipped, the leucine 717 would be substituted by a 
threonine, causing a generation of a premature stop codon after 51 codons 
(MYBPC3-L717TfsX51).  
Figure 19: Effect of the MYBPC3-c.2308+3G>C mutation on the splicing of exon 23 
of the MYBPC3 gene. (left) Electrophoresis of RT-PCR analyses of mRNA extracted 
from HEK293 cells transfected with pMG plasmids. Lane 1: Marker VI (Roche 
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Diagnostics); Lane 2: pMG WT; Lane 3: pMG 2308+3 G>C. (right) 
Electropherograms obtained from cDNA sequencing of the fragments; black, red, 
green and blue peaks represent the G, T, A, and C. Band a and band b sequences 
corresponded to the respectively band of pMG WT electrophoresis shown on the left. 
The electropherograms indicates the end of exon 2 and the start of exon 3 of HBB 
(highlighted in grey) and the start sequence of exon 23 of MYBPC3 cDNA 
(highlighted in yellow). 
4.3 Investigations on pathogenic mechanism of missense mutation  
The large genetic screening showed 43% mutations in MYBPC3 gene to be 
missense. As opposed to truncating mutations, the HCM-causing missense 
variants seem to localise more to the central domains of protein. Among them, 
a new missense variant, I603M, was found. The mutation is in the central 
domain C4. 
 
I603M was identified in a proband with clinical features of HCM and family 
history. The family screening evidenced the presence of mutation in affected 
subjects in heterozygosis together with another MYBPC3 mutation, 
T33RfsX15. Only one patient, corresponding to III.5, is clinical affected but 
did not show the I603M mutation. Furthermore, two young subjects result 
positive to genetic screening without clinical evidences for HCM (figure 20).  
 
Figure 20: pedigree of four generations of HCM family with p.I603M variant. Open 
symbols represent subjects with a negative phenotype. Black symbols represent 
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clinically affected subjects. Circles or square with solid centres indicate unaffected 
mutation carriers. The symptoms of each patient are indicated: SCD, Sudden Cardiac 
Death; AS, Aortic Stenosis; HCM, Hypertrophic cardiomyopathy; VH, Ventricular 
Hypertrophy; CoA, coarctation of the Aorta. y:years. 
Preliminary evaluation using three different bioinformatics tools showed 
strong evidence for deleterious effect of I603M variant (Table 8). Indeed, in 
comparison with another benign variant localised in the same domain, I603M 
showed a high score of pathogenicity.  
Table 8: bioinformatics prediction of deleterious effect of p.I603M 
 
 
Given the considerable evidence of deleterious effect, the variant I603M was 
selected for functional study to determine pathogenicity. 
 
4.3.1 In silico and in vitro study of splicing alterations induced by 
missense mutations 
Defects in RNA splicing is a mechanism by which missense mutations can 
result into truncated polypeptides, leading to protein haploinsufficiency that 
causes HCM. During the editing of pre-mRNA transcripts, the splicing 
machinery recognizes consensus sequences that also include the exons, 
particularly the regions close to the intron-exon boundaries (Yue et al. 2005; 
Lee and Rio 2015; Smelter et al. 2018). Several missense mutations of 
cMyBPC, whose pathogenicity status is well established, are known to cause 
RNA splicing disruptions (Carrier et al. 1997; Helms et al. 2014). We used 
available information to validate our in silico and in vitro analyses of RNA 
splicing alterations by mutations in exonic regions (missense mutations). 
The disease-causing missense mutation E542Q (c.1624G>C), located at 
central domain C3 of cMyBPC, has been shown to cause alterations of splicing 
in human myocardium (Marston et al. 2012). The Alamut analyses of this 
mutation predicted the loss of a splice site, with maximum probability score 
determined by two algorithms (SSF and NNSplice) (Figure 21). We examined 
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the alteration of mRNA for the mutated transcript experimentally on blood 
samples. The region between exon 15 and exon 21 of cMyBP-C’s mRNA was 
amplified using the leukocitary fraction of peripheral blood as starting 
material. In line with in silico prediction and the previously analyses on 
myocardial biopsies in literature (Carrier et al. 1997), the mutation E542Q 
induces the skipping of exon 17 (Figures 21, 22). This effect can be observed 
from the higher mobility band that is amplified (Figure 22), and confirmed by 
the Sanger sequencing results, in which to exon-exon boundaries are detected, 
one corresponding to normal processing of mRNA (exon 17-exon 18, from 
wild type allele) and the other one to the skipping of exon 17 (Figure 21). 
 
Figure 21: Splicing analyses of E542Q (c.1624G>C). (on the left) The histograms 
show the results of Alamut software. The canonic splice site loss has high score. No 
probability of new acceptor site creation was found. (on the right) Electropherogram 
obtained from cDNA sequencing of exon15-exon21 fragment, amplified from mRNA 
obtained from peripheral blood. The electropherogram indicates the end of exon 16 
and the start of exon 17 (top) or exon 18 (bottom) of cMyBPC. Black, red, green and 
blue peaks represent the G, T, A, and C. 
We also analysed splicing alterations in other disease-causing missense 
mutations affecting domain C3. Mutations R495Q (c.1484G>A), R502W 
(c.1504C>T) and R502Q (c.1505G>A) were predicted not to alter the 
canonical acceptor site. Only for R502Q, the Alamut software showed a 
potential new acceptor site (Figure 22). The effect of these mutations in the 
splicing of cMyBP-C’s mRNA was analysed using mRNA from peripheral 
blood of carriers. As opposed to E542Q, mutations R495Q, R502W and 
R502Q gave rise to bands of the same size as the wild-type (Figure 22). Sanger 
sequencing confirmed no alteration on the transcripts (Figure 22). Importantly, 
our results using peripheral blood are coincident with results obtained usind 
myocardial samples from patients carrying mutations R495Q and R502W 
(Marston et al. 2012; Helms et al. 2014).  
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Figure 22: Splicing analyses of R502Q, R495Q and R502W. (on the left) The 
histograms represent the results of Alamut software. The evaluations were carried out 
with five algorithms of splicing prediction: SSF (SpliceSiteFinder-like), MaxEnt, 
NNSPLICE (Neural Network Splice), GeneSplicer and HSF (Human Splicing 
Finder). No splicing alterations were predicted. (on the centre) Electropherograms 
obtained from cDNA sequencing of exon15-exon21 fragment. The electropherograms 
indicates the end of exon 16 and the start of exon 17 of cMyBPC. Black, red, green 
and blue peaks represent the G, T, A, and C. (on the left) Electrophoresis of RT-PCR 
analyses of mRNA. M: 1Kb DNA ladder; CTRL WT: amplification product of mRNA 
extracted from healthy subject; CTRL+: amplification product of commercial cardiac 
mRNA; CTRL-: amplification product of mRNA extracted from Hela cells as 
negative control. 
Overall, these analyses confirm that the pathological mechanism in missense 
mutations may occur as an mRNA defect rather than directly affecting the 
protein, such as in the case of E542Q. Defects in mRNA splicing for these 
mutations can be predicted with bioinformatics tools with high fidelity, and 
false positives can be avoided by analyzing readily available peripheral blood 
from patients.  
In the quest to describe pathogenicity for mutation I603M (c.1809T>G), we 
applied the same analyses of RNA splicing alterations. The mutation occurs in 
the exon 19. The transcript fragment spanning from exon 15 to exon 21 was 
amplified from blood’s mRNA. The electrophoresis gel showed an identical 
migration pattern of both mutant and WT fragments (Figure 23). The WT 
corresponded to a healthy subject. Sanger sequencing confirmed the correct 
splicing (Figure 23). 
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Figure 23: Effect of the MYBPC3-c.1809T>G (p.I603M) mutation on the splicing 
mechanism. (on the left) Electrophoresis of RT-PCR analyses of mRNA. Lane 1: 
Marker XIV (Roche Diagnostics); Lane 2: Control; Lane 3: c.1809T>G mutation. (on 
the right) Electropherograms obtained from cDNA sequencing of the fragments; 
black, red, green and blue peaks represent the G, T, A, and C. The electropherograms 
indicates the end of exon 17 (highlighted in grey) and the start sequence of exon 18 
of MYBPC3 cDNA (highlighted in green). 
 
4.3.2 Homology modelling of domain C4 structure 
The position of I603M mutation is mapped on the structure of central domain 
C4 of cMyBPC. Since the structure of domain C4 is not known, to predict how 
the protein structure might be affected by I603M mutation, the homology 
modelling of the domain was carried out. The protein sequence related to C4 
from the UniProt database was modelled using I-TASSER tool. The model 
showed that the C4 domain adopts an Ig-like folding (Figure 24,A) (Kufareva 
and Abagyan 2012). Instead, the prediction of mutant structure showed the 
same folding of WT (Figure 24,B). The RMSD of both predictions with respect 
to the template was 1.9±1.6Å for WT and 2.0±1.6Å for I603M. 
In the mutation, an isoleucine is substituted by another non-polar amino acid, 
methionine, suggesting no effect on protein structure. Still, it is interesting to 
observe that Ile603 is buried in the core of the domain, so a mutation affecting 
this residue could not be easily accommodated by the domain leading to 
potential destabilization of the I603M mutant.  
 
 Results 
 55 
 
Figure 24: Homology modelling prediction of cMyBPC C4 domain. (A) Graphic 
representation of secondary structure of C4 WT domain, modelled with I-tasser using 
slow-MyBPC as a template (2YUZ PDB structure). The position of the isoleucine 
replaced in HCM patients is shown in red. (B) Overlapping of the secondary structure 
predictions of C4WT and C4 I603M. The mutant domain is indicating in magenta. 
The models of C4 domain have been prepared with PyMOL. 
 
4.3.3 Structural and thermodynamic characterization of C4 and missense 
mutant by circular dichroism 
Since RNA splicing seems not to be altered by mutation I603M, we investigate 
whether structural and biophysical properties of cMyBPC C4 domain may be 
affected in the mutant. To that end, the recombinant WT (aa.544-aa.633) as 
well as mutant I603M proteins were expressed and purified using E.Coli 
BLR21 (DE3) expression system. Site direct mutagenesis by PCR was used to 
generate the I603M mutant domain. All proteins were expressed in soluble 
form and purified by two steps: nickel-nitrilotriacetic acid (Ni-NTA) 
chromatography and size-exclusion chromatography using a fast protein liquid 
chromatography (FPLC) system (AKTA, GE Healthcare). All domains were 
at least 90–95% pure as judged by SDS-PAGE analysis (Figure 25).  
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Figure 25: purification of recombinant C4 domain expressed in E.Coli BLR21 (DE3). 
Ni-Nta purification and gel filtration profile of the purified C4 WT (A) and C4 I603M 
(B). The nickel-nitrilotriacetic acid (Ni-NTA) pools were further purified with fast 
protein liquid chromatography (FPLC) using size-exclusion. All fractions were loaded 
in SDS-gels. The preparations were at least 90–95% pure. 
 
Both proteins were analysed by Circular Dichroism (CD) to determine their 
secondary structure and folding properties. To investigate potential structural 
changes induced by the I603M mutation, far-UV (250-195nm) and near-UV 
(350-250nm) CD spectra were collected at 25°C for both C4 WT and C4 
I603M (Figure 26).The spectra of C4 WT showed a minimum of ellipticity at 
215 nm, characteristic of β-sheet structure (Greenfield 2006; Shen et al. 2018) 
in agreement with the homology modelling prediction. The comparison 
between C4 WT and C4 I603M spectra showed a similar native structure 
suggesting that the mutation did not have major impact in the fold of the protein 
(Figure 26 C,D). Change in the shape of the far-UV spectra was observed when 
the sample temperature was increased to 85°C, indicating the unfolding of 
protein and loss of secondary structure for both WT and I603M (Figure 26 A, 
B). The maximum differences between spectra at 25°C and 85°C were 
observed at 205 nm and at 230 nm. These wavelengths were chosen for 
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tracking the thermal denaturation of the proteins, to examine whether the 
mutation induces any thermodynamical destabilization. 
 
 
Figure 26: circular dichroism spectra of cMyBPC C4 WT and I603M. CD spectra of 
C4 WT (A) and C4 I603M (B) monitored in the far-UV at 25°C (solid line) and 85°C 
(dashed line). (C) Comparison of CD spectra in far-UV of native C4 WT and C4 
I603M. (D) CD spectra of C4 WT and C4 I603M collected in near-UV. 
Temperature-induced protein unfolding was investigated by monitoring the 
ellipticity as a function of temperature. The CD signals at 205nm and 230nm 
were tracked over a temperature range from 25°C to 85°C. Data of both WT 
and I603M mutant were fit to sigmoidal curves. The unfolding profiles 
measured of the two proteins at 205nm showed different midpoint unfolding 
temperatures, with a melting temperature (Tm) of 57°C for C4 WT and 42°C 
for mutant C4 (Figure 27 A). Similar Tm values were obtained from the 
unfolding transition monitored at 230 nm: 58°C for WT and 45°C for the 
mutant (Figure 27 B) These data show the destabilizing effect of mutation 
I603M on the C4 domain.  
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Figure 27: temperature-induced unfolding of the C4 domain monitored by CD. (A) 
CD signal at 205nm for the C4 WT (dark green) and C4 I603M (light green) collected 
as a function of temperature. The Tm of C4 I603M (42°C) is indicated with light grey 
line; Tm of C4 WT (57°C) is indicated with dark grey line. (B) Ellipticity at 230 nm 
as function of temperature for C4 WT (dark green) and C4 I603M (light green). The 
light grey line indicates the Tm of C4 I603M (45°C); dark grey line represents C4 WT 
Tm (58°C). The fit of the data to the sigmoidal curves is shown in red. 
CD experiments to study refolding of domain C4 were carried out by ramping 
the temperature down while collected ellipticity. The refolding ability of the 
domains was determined by collecting a final far-UV CD spectrum at 25°C. 
Over 90% of the native protein refolded into original secondary structure after 
the cooling from 85°C to 25°C, for both WT and mutant I603M (Figure 28). 
Therefore, these data suggest that thermal denaturation of C4 WT as well as 
C4 I603M are reversible processes.  
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Figure 28: spectra characterization of the temperature-induced unfolding reversibility 
of C4 domain. Thermal denaturation (solid line) and renaturation (dashed line) of C4 
WT (A) and C4 I603M (C) collected as change of ellipticity during thermal ramp up 
(from 25°C to 85°) and thermal ramp down (from 85°C to 25°C). The far-UV CD 
spectra of C4 WT (B) and C4 I603M (D) of protein under native state (green traces) 
and refolded state (grey traces) are shown.  
 
When the unfolding of a protein is reversible and two-state, and there is only a 
single unfolding transition, the thermodynamic parameters evaluated by CD 
are almost identical with calorimetric methods (Greenfield 2007). The Gibbs-
Helmholtz equation was used to fit the change of ellipticity at a single 
wavelength as a function of temperature. Using this fitting the van’t Hoff 
enthalpy (∆Hv) was calculated from CD data at 205 nm A small difference in 
enthalpy was observed in WT and mutant proteins with ∆Hv of 280 kJ/mol for 
C4WT and ∆Hv of 276 kJ/mol for C4 I603M. The same fitting was calculated 
also from CD data at 230 nm, with lower noise. The resulting van’t Hoff 
enthalpy ∆Hv was different in WT and mutant, with ∆Hv of 220 kJ/mol for 
C4WT and ∆Hv of 130 kJ/mol for C4 I603M. 
4.3.4 Thermodynamic stability of C4-WT and C4-I603M 
The analysis of thermal stability by CD shows a marked decreased in Tm for 
the mutant, while the enthalpies of the unfolding transitions for the wild-type 
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and mutant I603M are very similar when monitored at 205 nm but different at 
230 nm. To explore thermodynamic parameters by a more direct approach, 
differential scanning calorimetry (DSC) was carried out on domain C4-WT 
and C4 I603M. The thermograms of both WT and mutant were obtained in 
phosphate buffer and recorded at a scan rate of 30°C/h, which are the same 
conditions employed in CD experiments. The thermal peaks of both proteins 
indicate an exothermic transition with heat release (Figure 29). The transition 
could be seen also when the C4 WT and C4 I603M were subjected to a second 
heating scan after it were cooled from the first run (data not shown), showing 
that the unfolding of both polypeptides was almost completely reversible.  
 
 
Figure 29: thermal unfolding monitored by DSC. Thermogram of C4 WT (A) and C4 
I603M (B). Processed experimental data after baseline subtraction are shown in green 
and the fit of the data to the two-state model is shown in red.  
The Tm values calculated in DSC are 58°C and 45°C for WT and I603M 
respectively, and were comparable to the values obtained in CD. The 
calorimetric enthalpy (∆Hcal) was calculated by integration of the area under 
the thermogram peak and resulted in 364 kJ/mol for C4 WT and 196 kJ/mol 
for C4 I603M. The van’t Hoff enthalpy (∆Hv) was determined by the two-state 
fit of the thermogram. Again, the ∆Hv for C4 WT results higher than the value 
for C4 I603M (330 kJ/mol and 222 kJ/mol, respectively). The ∆Hcal/∆Hv ratio 
is 1.1 for WT and 0.89 for mutant. These values of ratio are close to the range 
of experimental error, and confirm that the two-state model is a good 
approximation to the unfolding process of C4 WT and I603M. 
The Gibbs free energy change (ΔG) of the unfolding process was also 
calculated at 25°C considering ΔCp=0. The ΔΔG of C4 I603M resulted in 4.5 
kcal/mol, suggesting that the mutant is less thermodynamically stable than 
wild-type.  
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4.3.5 Mechanical characterization of cMyBPC C4 domain by Atomic 
Force Microscopy (AFM) 
Single molecule force spectroscopy has proven to be a powerful technique to 
study the mechanical properties of proteins as well as their conformational 
dynamics (Popa et al. 2013; Giganti et al. 2018). The information provided by 
force spectroscopy is particularly interesting for proteins that work under 
mechanical force, such as cMyBPC. Hence, we have studied the mechanical 
properties of C4 domain by single-molecule force-spectroscopy by AFM. 
 
In single-molecule AFM experiments, it is necessary to fingerprint events of 
interest. A straightforward manner of achieving molecular fingerprinting is by 
the use of protein engineering to produce heteropolyproteins that contain 
marker proteins, of known mechanical properties. When pulling 
heteropolyproteins, mechanical unfolding of its constituent domains produce 
repetitive events of certain lengths. Those events corresponding to the marker 
proteins are accompanied, in the same single-molecule recording, by events 
corresponding to the domain of interest. In our case, we chose to engineer a 
heteropolyprotein of the C4 domain and Protein L, (C4-L)4 (Figure 30 A). 
Protein L is naturally expressed in P. magnus as one of five homologous 
tandem domains. The protein is 63 amino acids in length and comprises a four-
stranded β-sheet packed against a single a-helix. The Protein L is characterised 
by small and simple topology, but remarkable mechanical stability (Brockwell 
et al. 2005). The unfolding length of protein L has already been characterized 
(Glyakina et al. 2009; Sadler et al. 2009; Valle-Orero et al. 2017; Pimenta-
Lopes et al. 2018). 
 
The (C4-L)4 heteropolyprotein was pulled at a constant velocity of 400nm/s to 
obtain the corresponding force versus extension curves. During force-
extension measurements the separation between the cantilever and the surface 
changes linearly with time. These experiments measure the force applied to the 
protein as a function of its extension, giving rise to sawtooth pattern traces of 
unfolding, in which each “tooth” represents the unfolding and extension of an 
individual domain. To obtain the contour length increment for each protein, 
we used the worm-like chain (WLC) model of polymer elasticity. A typical 
force-extension curve for (C4-L)4 is shown in Figure 30B. The last peak in the 
force-extension curve corresponds to the detachment of the polyprotein from 
the surface and/or the cantilever. In force-extension curves, the unfolding of 
Protein L is characterized by peaks around 100 pN with corresponding 
increments in contour length (∆c) of 19 nm (Sadler et al. 2009). Therefore, the 
unfolding events of Protein L provide a unique fingerprint that serves to 
identify successful traces. Surprisingly, no consistent unfolding peaks 
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assignable to the C4 domains were observed in these force-extension 
experiments, but only unfolding events corresponding to Protein L.  
As an alternative approach more suited to identify unfolding steps, (C4-L)4 
was pulled in force-ramp mode applying a constant force thanks to control of 
piezo-electric element (Popa et al. 2013). The unfolding events were registered 
as stepwise changes in protein length in an extension versus time curve. The 
force was linearly varied at a rate of 10 pN/s for up to 20 s. The typical force-
ramp trace showed four steps marking the unfolding of the Protein L, 17±1 nm 
long and occurring at around 50pN. As in force-extension recordings, no steps 
corresponding to the C4 domains were observed (Figure 30 C). 
 
Figure 30: (C4-L)4 heteropolyprotein investigated using single-molecule force-
spectroscopy by AFM. (A) Schematic representation of the heteropolyprotein 
construct with a combination of four C4 (grey structure) and four fingerprinting 
protein-L (red structure) domains, used to probe the mechanical response of domain 
C4. (B) Typical force extension trace that captures four unfolding events of protein-
L; no steps corresponding to the C4 domains were observed. The last event 
corresponds to the detachment of the polyprotien. WLC fit to the traces is shown in 
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red. The contour length (∆c) of 19 nm was measured for the four events, 
corresponding to L-Protein. The initial extension (L0) was calculated from 0 to the 
first unfolding event. (C) Representative force-ramp trace showed the extension of 
(C4-L)4 (red trace) and the force applied (black trace). Mechanical unfolding events 
of four Protein-L domains were detected, marked by unfolding lengths of 17±1 nm. 
In order to define the molecular fingerprint of C4 domains in an unbiased 
manner, the step size and unfolding forces of all force-ramp traces containing 
at least 2 steps were analysed. The step lengths and the corresponding 
unfolding forces were represented in a bidimensional histogram (Figure 31 A; 
N = 2170 events). The histogram displays only one well-defined population 
corresponding to Protein L with 15±1 nm long and occurring around 50pN, as 
expected from previous AFM characterization of the domain (Sadler et al. 
2009; Pimenta-Lopes et al. 2018). We conclude that there is no specific 
fingerprint associated with mechanical unfolding of C4 domain. 
 
To rule out the possibility that Protein L was interfering with the mechanical 
response of domain C4, mechanical characterization of C4 was carried out 
using a different marker protein, Sumo1. Sumo1 is one of the four small 
ubiquitin-related modifiers (SUMOs) with known mechanical characteristics 
(Kotamarthi et al. 2013; Kotamarthi et al. 2015; Pimenta-Lopes et al. 2018). In 
the same manner as above, 390 traces of (C4-Sumo1)4 under force-ramp, 
containing at least two events of the same size, were recorded and step size and 
unfolding forces were represented in a bidimensional histogram (Figure 31 B). 
Similar to results with (C4-L)4, the data highlighted only one population, with 
19±1 nm step size and around 130 pN unfolding force, which represent the 
Sumo1 protein. 
 
 
Figure 31: Fingerprinting of (C4-L)4 and (C4-Sumo1)4 heteropolyproteins. (A) 
Bidimensional histogram representing the step sizes and unfolding forces of 2170 
events recorded in force-ramp mode for (C4-L)4. A well-defined population 
 Results 
 64 
corresponds to unfolding of Protein-L (step size 15±1 nm at around 50pN) were 
identified. (B) Bidimensional histogram of the step sizes and the related unfolding 
forces from 390 AFM events of (C4-Sumo1)4 in force ramp-mode. A well-defined 
populations correspond to unfolding of Sumo1 (step size 19±1 nm at around 130 pN) 
is observed.  
The results of C4 fingerprinting are compatible with two different situations. 
The absence of homogeneous unfolding events coming from C4 might occur 
either if C4 extends before the first Protein L unfolding, or if it remains folded 
throughout the experiment. To determine which scenario is correct, the initial 
extension of the protein before the first Protein L unfolding event was 
estimated by fitting the worm-like chain model to the first unfolding peak of 
all traces that had the four Protein L events (n=10) (Figure 30 B). If the C4 
domains do not unfold before Protein L, the initial extension would be in the 
range of 29.9-39.6nm. This value was calculated as the sum of length of three 
or four C4 modules (4 nm per domain), 4 folded Protein L domains (3 nm per 
domain), the handles and linkers included in the polyprotein. In contrast, if the 
C4 domains are unfolded before the first unfolding of protein-L, the initial 
extension should be 125.6-167.2nm. These values correspond to the extension 
of folded Protein L, the handles, linkers and three or four unfolded C4 domain. 
An initial extension of 139 nm was obtained from a fit to the experimental 
histogram of initial extensions estimated using the WLC model (Figure 30 B, 
Figure 32). These data show that the C4 modules mechanically unfold before 
the Protein L modules.  
 
 
Figure 32: extensibility of C4 domain. Histogram of the initial extension for traces 
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with four L domains unfolding events (n=10). The expected initial extensions if the 
C4 behaved as random coils (dotted line on the left) or as mechanically stable domains 
(dotted line on the right) are shown. A Gaussian fit to the histogram is shown in red.  
To investigate the possibility that the mutation I603M induced mechanical 
stabilization of the domain C4, characterization of (C4 I603M-Sumo1)4 was 
carried out. The unfolding events were registered as changes in protein length 
in force-extension and force-ramp modes, as for the wild-type protein. Again, 
the typical force-extension trace showed four steps marking the unfolding of 
the Sumo1 and no steps corresponding to the C4 domains were observed 
(Figure 33 A). 890 traces under force ramp were recorded and analysed in order 
to define the mechanical fingerprinting of the mutant. Similarly, the 
bidimensional histogram highlighted only one population, with 19±1 nm step 
size and around 130 pN unfolding force, which represents the Sumo1 protein 
(Figure 33 B). Hence, it is concluded that the mutation does not induce 
mechanical stabilization within the sensitivity of the AFM measurements. 
 
 
Figure 33: Fingerprinting of (C4 I603M-Sumo1)4 heteropolyprotein. (A) Typical 
force extension trace represents four unfolding events of Sumo1; no peaks 
corresponding to the C4 domains were observed. The four peaks correspond to Sumo1 
with a contour length (∆c) of 24 nm, measured with using the WLC model (in red) 
(B) Bidimensional histogram representing the step sizes and unfolding forces of 890 
events recorded in force-ramp mode for (C4-Sumo1)4. A well-defined population 
corresponds to unfolding of Sumo1 (step size 19±1 nm at around 130pN) was 
identified.  
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5.DISCUSSION 
In the last few years, there has been an increasing interest in personalized 
medicine based on an individual’s genes, environment, and lifestyle (Auffray 
et al. 2016; Nimmesgern et al. 2017; Scherr et al. 2018). The goal of Precision 
Medicine Initiative (PMI) is the identification of personalized interventions 
that not only include treatment, but also more targeted and cost-effective 
prevention and early-detection strategies. For those reasons, research has 
intensified to improve the understanding of disease mechanisms, diagnosis, 
and treatment outcomes mining the results of extensive genomic sequencing 
projects.  
 
However, what do people want to know about their genes? According to a 
recent review, when asked about hypothetical genetic testing, most subjects 
would like to know all results except those that are uncertain, such as variants 
of uncertain significance (VUS) (Scherr et al. 2018). Indeed, in genetic screens 
of hereditary disorders, several different types of variants can be found and 
classified as pathogenic mutations, benign polymorphisms or VUS according 
to their known health impacts (Hershberger et al. 2018). The majority of 
clinical variants across all genes are currently classified as VUS. A recent 
study, indeed, show that in ClinVar, VUS constitute over 50% of entries for 
missense variants (Figure 33) (Weile and Roth 2018). The increase in relative 
and absolute number of VUS variants over the last few years is astonishing, 
and reflects the broad availability of Next Generation Sequencing (NGS) 
techniques (Figure 33). 
 
 
 
Figure 34: variants of uncertain significance (VUS) recorded in Clinvar database. The 
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for known disease-associated genes and even whole-exome 
sequencing (WES) are widely commercially available. A 
number of different standards fo  classifying mutations 
with respect to their potential health impacts have been pro-
posed; most prominently, the American College of Medical 
Genetics and Genomics (ACMG) standard (Richards et al. 
2015). It defines categories str tching from “pathogenic” 
to “benign”, including the ‘gray zone’ category of “variant 
of uncertain significance” (VUS). Even though the muta-
tional landscape for a handful of genes, such as BRCA1 are 
explored better than others due to their established relevance 
and potential for taking clinical action (Cheon et al. 2014), 
the majority of clinical variants across all genes are currently 
classified as VUS. In ClinVar alone, VUS make up over 
50% of entries for missense variants (Fig. 1), despite ClinVar 
guidelines that actively discourage submission of unclassi-
fied variants. In a recent study using gene panels assessing 
germline cancer risk loci (Maxwell et al. 2016), over 98% 
of missense variants were classified as VUS. Not only can 
these uncertainties burden patients with unnecessary anxi-
ety (Cheon et al. 2014), they also call into question the value 
of sequencing in the clinic if the majority of findings are 
not actionable. With increasing use of WES and WGS as 
opposed to targeted gene panels, this problem is only going 
to get worse. According to the 1000 Genomes Project data, 
every person carries 100–400 missense variants that are 
so rare that they have likely never been seen before in the 
clinic (The 1000 Genomes Project Consortium 2015). In the 
absence of the previous observations, they would automati-
cally be added to the long list of VUSs.
Like its sister standards, the ACMG guidelines also rec-
ognize different methods of gathering evidence towards a 
variant’s classification. These can be broadly summarized 
as (1) frequency of observation in affected or unaffected 
individuals; (2) laboratory assays; and (3) in silico predic-
tion. Out of these three categories, in silico prediction used 
to be the only option that easily scaled to cover all possible 
variants and could be applied proactively. However, it is 
also considered one of the weakest forms of evidence. Over 
the last decade, however, a new type of high-throughput 
laboratory assay has emerged: Multiplexed Assays of Vari-
ant Effect (MAVEs) (Starita et al. 2017), which promise to 
massively increase the scalability of those methods that the 
ACMG considers in the highest tiers of evidence. In the fol-
lowing, we will first recapitulate some of the more popular in 
silico approaches and then discuss MAVEs, breaking down 
the methodological variety in the existing studies, describ-
ing some of the newest developments and their implications 
for the future.
In silico approaches to variant function 
assessment
A number of algorithms exist that offer predictions as to 
the deleteriousness of mutations, with prominent examples 
including PolyPhen-2 (Adzhubei et al. 2013), SIFT (Ng 
and Henikoff 2001), and PROVEAN (Choi et al. 2012). 
PolyPhen-2 employs a simple (naive Bayes) machine learn-
ing method based on evolutionary conservation and pro-
tein structural features. It uses a set of previously reported 
pathogenic alleles as a positive training set and differences 
between human genes and their mammalian homologues as 
a negative training set. By contrast, SIFT (Sorting Intolerant 
From Tolerant) only uses evolutionary conservation. The 
tool uses multiple sequence alignments to calculate position-
specific score matrices for each gene which are then normal-
ized and transformed into probability values. PROVEAN 
(PROtein Variation Effect ANalyzer) similarly only takes 
into account sequence alignments. However, rather than 
just computing a position-specific score, PROVEAN calcu-
lates the difference in alignment quality between using the 
wild-type or variant sequence against clusters of homolo-
gous sequences. The average distance is then interpreted as 
indicative of the deleteriousness of the variant.
While the three tools succeed in making good predic-
tions, their reliability is unfortunately still not high enough 
to serve as a basis of clinical decision making. We and oth-
ers recently performed an independent comparison of these 
tools on a set of well-established disease-causing variants 
as well as rare polymorphisms with no known disease asso-
ciation (Sun et al. 2016). The study examined the trade-
off between precision (the fraction of pathogenic variant 
Fig. 1  Percentage of variants of uncertain significance (VUS) among 
missense allele Clinvar records over time from 1990 until 2017
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histogram represents the percentage of missense VUS records over time from 1990 
until 2017.(Adapted from Weile and Roth 2018)  
Hypertrophic cardiomyopathy (HCM) is the most common familial heart 
disease with vast genetic heterogeneity (Burke et al. 2016; Liew et al. 2017; 
Sabater-Molina et al. 2018). The disease is caused by mutations in genes 
coding for sarcomeric proteins. Among them, cardiac myosin-binding protein 
C (MYBPC3) and β-myosin heavy chain (MYH7) genes are responsible for 
approximately half of the familial HCM cases.  
 
The identification of HCM-causative mutations has revolutionized clinical 
management of patients and their families. Indeed, genetic testing is 
recommended after the initial identification of a pathogenic variant in order to 
classify asymptomatic relatives who might be at risk of disease-related 
complications, such as the risk of sudden cardiac death. However, the 
identification of VUS limits the reach of genetic testing in clinical practice due 
to the absence of pathogenicity assignment (Semsarian et al. 2015). Just think 
of MYBPC3, whose VUS constitute 44.6% of entries for missense variants 
shown in ClinVar database. Moreover, this percentage increases (66,5%) when 
all the mutations correlated to HCM are considered. Notably, the Association 
for Clinical Genetic Science does not recommend predictive testing on family 
members following the finding of a VUS in an index case (Ellard et al. 2017). 
Functional assessment of VUS can help define their pathogenic nature. 
5.1. Selection of genetic variants for further functional screening 
In this thesis the pathogenic effects of new genetic variants in MYBPC3 related 
to HCM have been investigated. MYBPC3 is the most frequently mutated gene 
in the cohort analysed. Indeed, 41% of the mutations found target MYBPC3. 
Similar numbers have been found in other genetic screens of HCM populations 
(Burke et al. 2016; Liew et al. 2017). Among the mutations targeting 
MYBPC3, seven variants had not been previously reported. Except for the null 
mutations, which by their nature have strong evidences of pathogenicity, 
c.506-2A>C, c.2308+3G>C and p.I603M variants can be classified as VUS 
and therefore were selected for functional studies.  
Another missense mutation, p.T705K, had not been reported before. This 
mutation was excluded from functional study due to the absence of family 
genetic screening. Clinical cosegregation evidence could support further 
functional study of this variant in the future. 
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5.2 Pathogenicity study for c.506-2A>C and c.2308+3G>C variants 
The c.506-2A>C and c.2308+3G>C are intronic variants. Intron variants play 
a crucial role in the aetiology of inherited cardiac conditions including 
cardiomyopathies. Indeed, approximately 10% of pathogenic variants causing 
cardiomyopathy are intronic mutations that lead to defects in alternative 
splicing mechanisms (Salman et al. 2018). Verification of a potential disease-
related mutation was performed using in silico procedures and in vitro 
functional analysis of the process of RNA splicing.  
 
The c.506-2A>C mutation disrupting the canonical AG/GT dinucleotides 
required for splicing resulted in a splice defect and the use of a cryptic acceptor 
site 7 nucleotides downstream (Figure 34). In the case of this variant, there was 
a 100% concordance between the in silico prediction, which highlighted the 
activation of a cryptic 3′ splice site, and the experimental results obtained using 
mRNA from the patient’s blood (Figure 18).  
 
Figure 35: schematic representation of the splicing alteration induced by c.506-2A>C 
mutation. The arrows represent the intron removal during the splicing process (green 
arrow for canonical splicing and red arrow for mutant). The red box indicates the loss 
of seven nucleotides induced by the mutation. The A>C in red is the position of the 
mutation. The number in grey is the canonical acceptor site; the red number is the 
cryptic acceptor site. 
 
Bioinformatics analysis of MYBPC3-c.2308+3G>C revealed that the score of 
the canonical donor splice site was decreased using all five prediction tools 
implemented in Alamut, and the decrease exceeded 50% for two of the 
prediction tools. Accordingly, minigene analysis of the mutated construct 
revealed skipping of MYBPC3 exon 23. In addition, HEK293 cells transfected 
with the WT minigene showed the coexistence of normal and skipped 
transcripts.  
 
The aberrant splicing in WT sequence of MYBPC3 has also been described in 
a recent study (Ito, Parth N Patel, et al. 2017). The cell splicing assay in 
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HEK293 of MYBPC3’s VUS, performed by Ito et al., show a high percentage 
of aberrant splice fragment in WT. In particular, the fragments including the 
WT donor site 2308G results in 25% of aberrant splicing, 75% without splice 
and only the 0,6% of fragments are processed canonically (Dataset S6 of Ito et 
al. 2017). We also implemented the minigene assay to study variants of C3 
domain of MYBPC3, including exon 16 and 17. These assays also showed 
aberrant splicing in WT, including intron retention as well as exon 16 skipping 
(data not shown). Together, these data suggest that some canonical splice sites 
of MYBPC3 are weak and are not always recognized in HEK293 cells. Hence, 
minigene strategies have limited utility to examine the effect of mutations in 
RNA processing. Preferred methods involve the analysis of the patient’s 
mRNA from myocardial or blood samples. 
 
Finally, this study highlights the relevance of functional analysis to verify the 
pathogenicity of intronic variants, especially those that are located in exon-
intron boundary. Hence, their importance in the diagnosis of HCM cannot be 
neglected, in agreement with recent reports using whole-genome sequencing 
(Bagnall et al. 2018). 
 
5.3 Pathogenicity study for p.I603M variant 
The p.I603M is a missense variant that affects a highly conserved residue in 
the central domain C4 of cMyBPC (Figure 35).  
 
Figure 36: sequence alignment of Human cMyBPC C4 domain with other species. 
The red bar indicates the I603. 
Results show that the variant c.1809T>G-p.I603M does not induce alterations 
in RNA splicing (Figure 23). At the protein level, the variant does not perturb 
much the structure of domain, according to the far-UV and near-UV CD 
spectra (Figure 26), in agreement with the homology models (Figure 24). Only 
small differences in the far-UV CD spectrum were observed in the range from 
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200nm to 205nm, which may be due to artefacts in a region of the spectra with 
higher noise. Although the mutant domain retains similar-to-WT structure, its 
thermodynamic stability is severely compromised, as shown by lower Tm in 
thermal denaturation experiments by CD and DSC, and by estimation of 
thermodynamic parameters by DSC. 
 
The thermodynamic parameters obtained by CD at 205 nm provide very 
similar values of ∆Hv for WT and I603M (Table 9). Contrariwise, the van’t 
Hoff enthalpy derived from CD at 230 nm result in a clear difference between 
WT and I603M. This contradiction probably reflects the fact that by using a 
single wavelength to monitor protein unfolding, we miss information about the 
global process of unfolding. In addition, the ∆Hv of CD estimated at 205 nm 
could be influenced by the higher noise of the experiment, and by the potential 
differences in the spectra at this region between wild-type and I603M (Figure 
27 A, 26 C). In this regard, more accurate measurments of thermodynamic 
parameters can be obtained using DSC. The Tm values obtained by DSC 
resulted equal to CD and the thermodynamic parameters expressed as ∆Hv 
confirmed a strong difference between WT and I603M (Table 9).  
 
Table 9: thermal stability parameters calculated by CD and DSC 
 Tm  CD 
∆Hv 
CD205 
∆Hv 
CD230 
Tm 
DSC 
∆Hv 
DSC 
C4 WT 57°C 280 kJ/mol 220 kJ/mol 58°C 330 kJ/mol 
C4 I603M 42°C 276 kJ/mol 130 kJ/mol 45°C 222 kJ/mol 
 
The Gibbs free energy change (ΔG) at 25ºC of the unfolding process was also 
calculated from the DSC thermograms. Since the thermograms of both WT and 
I603M did not allow accurate estimation of ΔCp, the derivation of ΔG was 
carried out considering ΔCp=0. Using this approximation, the resulting ΔΔG 
of C4 I603M is 4.5 kcal/mol. Such degree of destabilization has been linked 
with pathogenicity in other domains of cMyBPC (Suay-Corredera et al. 2018). 
In that report, which analysed dozen of missense variants in cMyBPC, a 
specific feature of pathogenic mutations was strong thermodynamic 
destabilization over non-pathogenic variants. Values of ΔΔG higher than 3.0 
kcal/mol were specifically associated with pathogenic mutations (Figure 37).  
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Figure 37: In silico examination of cMyBPC thermodynamic stability using the 
software FoldX. Each bar corresponds to ΔΔG calculated for a single variant. Pink 
bar correspond to pathogenic mutation, green bar correspond to non-pathogenic. The 
dotted line marks the highest change in ΔΔG detected for a non-pathogenic variant. 
(Figure adapted from Suay-Corredera et al. 2018). 
Altogether, these data suggest that the mutant C4 I603M is much less 
thermodynamically stable than wild-type. Hence, it can be concluded that the 
I603M variant alters the stability of the central C4 domain of cMyBPC, which 
can lead to more frequent protein unfolding, degradation and protein 
haploinsufficiency, a hallmark of HCM (Van Dijk et al. 2009; Marston et al. 
2009; Marston et al. 2012; Ito, Parth N. Patel, et al. 2017).  
Finally, the mutation I603M was identified in clinical affected subjects in 
combination with another truncating variant of cMyBPC (T33RfsX15) (Figure 
20). There is only one subject of the family that has cardiac hypertrophy in the 
absence of the mutation I603M, although the clinical manifestations probably 
are secondary to the coarctation of the aorta caused by an accident. In addition, 
there is one patient that carried only the truncated mutation and does not show 
HCM phenotype. The analysis of cosegregation of mutations in this family 
reflects the difficulties associated with genetic testing in a clinical setting, and 
the advantages offered by functional assessment of mutations. Overall, we can 
conclude that the mutation I603M is most likely pathogenic and that the 
presence of both mutated alleles can contribute synergistically to the clinical 
manifestation of HCM. 
5.4 Pathogenic mechanisms of intronic and missense mutations in HCM 
The functional study of intronic variants highlight the splicing defect affected 
by mutations. Usually, alternative splicing influences the structure of the 
mRNAs and their potential encoded proteins. The alternative splicing of 
mRNA is very important for the production of proteins with the right 
functionality, both in homeostasis and during development. The first study 
which showed the alternative splicing correlated with the contractile properties 
of embryonic myocardium regarded cardiac troponin T (cTnT) (Cooper and 
18 
 
Figure 1. In silico examination of protein haploinsufficiency drivers induced by putative missense 
mutations in MYBPC3. (a) Left: schematic representation of the region of the sarcomere where cMyBP-
C molecules are located. Positions of the Z- and M-lines are indicated. Middle: Around half of the HCM-
causing mutations in cMyBP-C lead to truncated polypeptides and protein haploinsufficiency. The 
remaining mutations are putative missense leading to single amino-acid substitutions in cMyBP-C. 
Right: ca diovascular-event-free survival probability Kaplan-Meier curves for carriers of truncating 
(purple) or missense (yellow) pathogenic or likely pathogenic mutations in MYBPC3 (the number of 
patients analyzed is indicated). Log-rank test, p = 0.01. (b) Effect of cMyBP-C missense variants on 
canonical RNA splicing predicted by the software Alamut. Each bar corresponds to a mutation. Bars are 
colored according to their predicted effect on RNA splicing: white, no alteration on splicing; black, loss 
of native site; gray, appearance of an alternative splicing site; black-and-gray, both loss of native site 
and appearance of an alternative one. The upper half, in pink, shows predictions for pathogenic 
mutations, whereas the lower half, in green, does th  same for the non-pathogenic variants. The tested 
v riants are spread throughout all cMyBP-C sequence, from domain C0 to C10 (organization of domains 
is indicated at the bottom of the panel; blue triangles indicate exon-exon boundaries along the amino-
acid sequence of cMyBP-C). (c) Effect of cMyBP-C missense variants on protein thermodynamic 
stability, measured as ΔΔG, using the software FoldX. Each bar corresponds to a single variant. Bars are 
colored according to the pathogenic status of the mutation (pathogenic, pink; non-pathogenic, green). 
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Ordahl 1985; McAuliffe et al. 1990; Godt et al. 1993). In the embryonic heart, 
the inclusion of exon 5 of cTnT in mRNAs makes embryonic myofibrils more 
sensitive to calcium than adult and thereby influences the contractile properties 
of embryonic myocardium (McAuliffe et al. 1990; Godt et al. 1993). TnT is 
not the only protein influenced by alternative splicing in heart. Other genes, 
such as myomesin (Myom1), titin (ttn) and LIM domain-binding 3 (Ldb3) have 
been shown to have alternative splicing mRNA which leads to isoforms with 
distinct functions.(Huang et al. 2003; Lahmers et al. 2004; Schoenauer et al. 
2011). However, any protein whose mRNA undergoes splicing is a potential 
target of mutations that disrupt this process, which can cause disease (Xiong 
et al. 2015). In cardiomyopathy, abnormal splicing of sarcomeric and ion 
channel genes has been reported in several studies. These changes can 
ultimately alter the normal internal architecture and homeostasis of the heart 
leading to heart failure (Lara-Pezzi et al. 2013; Van Den Hoogenhof et al. 
2016; Zhu et al. 2017; Noyes et al. 2017). 
The effect of mutations that alter the splicing process can be related to the 
activation of the nonsense-mediated decay (NMD) pathway. NMD is the 
process by which aberrant mRNAs containing premature termination codons 
(PTC) are targeted for accelerated degradation (Maquat 2004; Brogna and Wen 
2009). This process is thought to protect cells from the potentially deleterious 
effects of inappropriately truncated proteins. The NMD has been shown to be 
the major pathway involved in clearance of MYBPC3 mRNA with PTC 
mutations in mice (Vignier et al. 2009). The transcript degradation via NMD 
pathway reduces mutant allele expression and the total amount of proteins is 
decreased. When the normal allele expression is insufficient, the 
haploinsufficiency model could explain the pathogenicity effects. However, 
previously studies have already shown that the reduced expressions of 
cMyBPC are correlated with HCM development and contractile deficits of 
affected patients (Van Dijk et al. 2009; Marston et al. 2009; Harris et al. 2011). 
Regarding exonic variants, the most frequent mutations found in cMyBPC are 
truncating. Although protein truncation can result in normal levels of mutated 
mRNA, no detectable truncated polypeptide has been found in the myocardium 
of patients. The absence of truncated products is due to the degradation of 
aberrant polypeptides by cellular protein quality control systems, such as the 
ubiquitin proteasome system (UPS). The UPS represent the major eukaryotic 
proteolytic pathway (Ciechanover 1998). This degradation system, through an 
enzymatic complex (E1/E2/E3) marking proteins by polyubiquitination, which 
tags them for destruction by the 26S proteasome (Wilkinson 2000; Pickart and 
Cohen 2004; Xu et al. 2009). A number of E3 ligases have been shown to 
ubiquitinate misfolded proteins in an Hsp70-dependent manner (Arndt et al. 
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2007; Vembar and Brodsky 2008). Thus, the thermal instability, which leads 
the increasing of unfolding fractions of mutated proteins, can make them more 
sensitive to degradation. This mechanism could potentially contribute to the 
molecular pathogenesis of HCM.  
Finally, we can conclude that both the alteration of RNA splicing and the 
thermodynamic destabilization of cMyBPC may lead to reduced protein levels, 
similar to the situation induced by truncating mutations, contributing with the 
HCM pathogenesis through haploinsufficiency. This model is supported by 
bioinformatics predictions and experimental data with domain C3 (Suay-
Corredera et al. 2018). 
However, mutations can also perturb protein-protein interactions. Indeed, 
mutations of sarcomeric components that affect the thermodynamic stability 
leads to alterations in protein binding and are correlated with HCM phenotype 
(Kremneva et al. 2004; Armel and Leinwand 2010; Da’as et al. 2018). 
Although the central domains of cMyBPC, including C4, are not described to 
interact with actin or myosin, we cannot entirely discount this possibility. 
Certainly, much remains to be learned about the specific function of central 
domains of cMyBPC.  
5.5 Functional characterizations of VUS 
Mutations in cMyBPC currently pose a major challenge to genetic diagnosis, 
since it is hard to move variants into the “likely pathogenic” category for any 
given individual. According to the American College of Medical Genetics and 
Genomics (ACMG), in the absence of enough genetic support, the most 
important criterion to establish causality of putative disease-causing mutations 
is a functional study to estimate the impact of mutations on a gene or protein 
function.  
 
In summary, we propose a useful strategy to determine pathogenicity (Figure 
37). When variants occur in introns as well as in the splice site of exon regions, 
the bioinformatics analyses with SSF, MaxEnt, NN Splice, GeneSplicer and 
HSF can be used to evaluate the splicing mechanism (Figures 17, 21, 22). 
Among the results, splice site loss is a strong prediction of alterations that can 
be confirmed with experimental mRNA analyses. According to our results, 
validation of predicted new splicing sites is a strict requirement to discriminate 
frequent false positives (Figure 17, 19). Ideally, for tissue-specific gene 
expression, mRNA should be extracted from the corresponding tissue, which 
in the case of the heart can be challenging. We have been confirmed that the 
MYBPC3 ectopic mRNA in blood sample gives equivalent results to cardiac 
tissue (Figure 22). In those cases where samples from HCM patients is 
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unavailable, the minigene system is a viable alternative to investigate splicing 
mechanism (Figure 19), although the analysis for some specific splicing 
reactions can be challenging in this system (Ito, Parth N Patel, et al. 2017).  
 
Similarly, the first evaluations of pathogenicity of missense variants is 
bioinformatics. In silico profiling can be used to predict protein 
thermodynamic stability (C. Suay-Corredera et al. 2018). Mutations that target 
proteins for which high resolution structures are not available cannot be 
screened accurately for thermodynamic destabilization in silico, and therefore 
need to be studied experimentally. Both Circular Dichroism and Calorimetry 
have been demonstrated to highlight structural alterations as well as 
thermodynamic phenotypes.  
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Figure 38: flowchart of functional determinations of VUS.  
 
In summary, we propose that determination of RNA splicing and protein 
thermodynamic phenotypes can define HCM pathogenicity.  
 
However, many missense pathogenic mutations in cMyBPC do not alter RNA 
splicing nor protein thermodynamic stability, resulting in stable proteins that 
are predicted to be readily incorporated in sarcomeres (Marston et al. 2012; 
Helms et al. 2014). In this case the study of pathogenicity should be focused 
on the other mechanisms. A plausible scenario is the alterations of binding to 
actin and/or myosin or other interactor who are involving in cardiomyocyte 
function as well as development (Vignier et al. 2009; Davis et al. 2016). 
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Recently, single-molecule AFM data suggested another alternative mechanism 
to explicate HCM pathogenicity. Indeed, any missense mutants, localized in 
central domain of protein, leads to nanomechanical destabilization of cMyBPC 
causing the alterations in the dynamics and strength of cMyBPC tethers in the 
sarcomere. This mechanical changes, resulting in altered regulatory properties 
of the mutated proteins, may be cause the pathogenicity of HCM.  
 
Hence, it is highly recommended to study alternative pathogenic drivers for 
those variants that remain classified as VUS. 
5.6 Mechanical characterization of cMyBPC C4 domain 
The cMyBPC is a protein that works under mechanical force since it is tethered 
to the thick and thin filaments, which slide past each other during contraction. 
Hence, the study of mechanical properties of cMyBPC is of particular interest.  
 
Single-molecule AFM experiments of cMyBPC show no consistent unfolding 
peaks assignable to the C4 domains (Figure 31). The absence of mechanical 
fingerprinting can be concluded because C4 extends before the first L 
unfolding, as demonstrated in the study of initial extensibility (Figure 32). The 
mutant I603M was also tested and revealed a same absence of mechanical 
stability then WT domain. 
 
In light of these results, the central structure of cMyBPC should be examined 
more carefully. Interestingly, there is a 10-amino-acid segment between 
domains C4 and C5, which forms a flexible linker (Figure 38) (Idowu et al. 
2003). The length of this linker is longer than the one found in slow skeletal 
isoform of myosin-binding protein. Indeed, typical linker lengths in poly-Ig 
proteins is shorter than 10 amino acids, suggesting that the extra length of this 
particular linker may be required to stabilize C4 and/or C5 domains. In 
agreement with this hypothesis, CD analyses on C5 domain shows the 
importance of a part of this linker in the stability of the C5 (Idowu et al. 2003). 
Consequently, we plan to examine the high-resolution crystallographic 
structure of C3-C5 multidomain construct, and to undertake single-molecule 
AFM experiments with the same construct.  
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Figure 39: Sequence alignment of the C5 domain and part of the C4 domain with 
other Ig domains of known structure (from titin: tit_m5 PDB: 1nct; tit_i27 PDB 1tit 
and from telokin: 1tlk). The alignment is based on a comparison of the NMR structure 
of cC5 with the structure of the other Ig domains (Adapted from Idowu et al. 2003).  
Nevertheless, it cannot be excluded that the force range of single-molecule 
AFM is high for detect mechanical unfolding transitions of the C4 domain. To 
test this hypothesis, we plan to do experiments by magnetic tweezers, another 
single-molecule manipulation techniques that has better resolution at low 
forces (Neuman and Nagy 2008; Popa et al. 2016). 
 
 
 
 
work. Wild-type cC5, the mutant W71F and the
clinically relevant mutant R14H (see below) are
perfectly well folded. This is indicated by the
presence of well dispersed peaks on the extreme
left (low field) and right (high field) of the
spectrum. Peaks on the left are mainly backbone
amide proton resonances. Amide protons in hydro-
gen bonds tend to be shifted to the low field end of
the spectral range at about 10 ppm. Peaks on the
high field end of the spectrum at about 0 ppm are
aliphatic side-chain protons. The main contribution
to their position in the spectrum is the proximity of
the protons to aromatic amino acids, which can
shift peaks far away from their random coil
position. In contrast, the mutant N-short and the
clinically important N115K show spectra character-
istic of unfolded proteins in which the peak dis-
persion typical of folded proteins is absent. On
closer inspection, some weak peaks can be identi-
fied close to the position of the dispersed peaks in
the spectra of the folded constructs. These samples
might therefore contain an equilibrium of a large
amount of unfolded protein and a small amount
of protein containing some residual structure.
The wild-type cC5 and the FHC-linked R14H
and N115K mutants were characterised in more
detail by urea denaturation monitored by the
intrinsic tryptophan fluorescence of the protein
and by thermal denaturation monitored by 1D
NMR spectroscopy. Monitoring the thermal
unfolding by CD spectroscopy did not give satis-
factory results, as no clear melting transition point
could be identified (data not shown). Initial
attempts at monitoring the unfolding process
using tryptophan fluorescence failed because of
the presence of two tryptophan residues in cC5.
While one tryptophan (Trp43) occupies the highly
conserved tryptophan position of the IgI fold6
(Figure 5), the second tryptophan Trp71 is part of
the flexible cardiac-specific insertion in the CD
loop. As such, as also shown by NMR spectroscopy
(Figure 6), it is highly flexible and unrestrained by
Figure 5. Sequence alignment of domain 5 (and part of domain 4) from MyBP-C with IgI domains of known
structure. (a) Sequence alignment based on a comparison of the NMR structure of cC5 with IgI domains of known
structure (from titin: tit_m5 PDB: 1nct; tit_i27 PDB 1tit and from telokin: 1tlk). (b) Sequence alignment of the C4–C5
linker region based solely on sequence similarity. Card stands for cardiac, ssk for slow skeletal and fsk for fast skeletal
isoforms of MyBP-C. The b-strands of cC5 are indicated below the alignment. Residues are colour-coded when their
predominant feature is conserved to at least 80% in all sequences. Green, hydrophobic; red, negative charge; blue, posi-
tive charge; magenta, hydrophilic; orange, glycine; yellow, proline. The residue numbering is for the construct of C5
from human cardiac MyBP-C as used in this study. Details of the alignment are as described in Materials and Methods.
750 Central Domain of Cardiac MyBP-C
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6.CONCLUSIONS 
The conclusions of this thesis can be summarized as follows: 
1. three new mutations in Myosin Binding Protein C have been described; 
2. the study of the RNA splicing process show that in silico evaluations 
are efficient to predict canonical splice site loss, but can be unreliable 
to determine cryptic splice site acquisition; 
3. the analyses of mRNA of MYBPC3 in peripheral blood gives 
equivalent results to mRNA obtained from cardiac tissue, and hence, it 
is useful to study the effects of mutations in the splicing process; 
4. mutations c.506-2A>C and c.2308+3G>C lead to altered splicing and 
are predicted to be pathogenic; 
5. the C4 domain of cMyBP-C is thermodynamically stable but appears 
to be mechanically weak; 
6. the mutation I603M induces strong mechanical destabilization of the 
domain C4, pointing towards its pathogenic nature; 
7. the study of the functional consequences of mutations leads to 
assignment of pathogenicity of variants of uncertain significance.  
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